Method for identifying metastatic sequences

Abstract

The invention relates to methods for the identification of metastatic sequences. Cells from a cell line or an animal tissue are treated to form a cell line predisposed to metastasis. Treated cells are implanted in an animal of at a primary site and incubated for a period of time sufficient for the cells to proliferate and develop metastases at secondary sites. Expressed sequences from cells at the primary and secondary sites are amplified by differential display polymerase chain reaction and compared. Differentially expressed sequences are identical identified and can be cloned and sequenced. These sequences can be used as probes in the diagnosis of metastatic disorders, as probes to isolate metastatic sequences and as a therapeutic agent.

Description

REFERENCE TO RELATED APPLICATION

This patent application is a continuation of This application is a continuation of U.S. application Ser. No. 09/469,316, filed Dec. 22, 1999, which is a broadening Reissue Application of U.S. Pat. No. 5,783,182, issued Jul. 21, 1998. The patent application issuing as U.S. Pat. No. 5,783,182 claims priority on United States provisional patent application, serial number 60/006,838, filed Nov. 16, 1995.

More than one reissue application has been filed for the reissue of U.S. Pat. No. 5,783,182. Application Ser. No. 09/469,316, filed, now abandoned, is a reissue application of U.S. Pat. No. 5,783,182. Application Ser. No. 09/977,371, filed Oct. 16, 2001, is a continuation of Ser. No. 09/469,316 and a reissue of U.S. Pat. No. 5,783,182. Application Ser. No. 09/985,799, filed Nov. 16, 2001, is a continuation of Ser. No. 09/977,371 and a reissue of U.S. Pat. No. 5,783,182.

RIGHTS IN THE INVENTION

This invention was made in part with United States Government support under grant number CA350129, awarded by the National Cancer Institute, National Institute of Health and the United States Government has certain rights in the invention.

BACKGROUND

1. Field of the Invention

The present invention relates to methods for the identification and isolation of metastatic sequences, to diagnostic probes and kits which contain metastatic sequences and to therapeutic treatments for neoplastic disorders based on metastatic sequences.

2. Description of the Background

The development of higher organisms is characterized by an exquisite pattern of temporal and spatially regulated cell division. Disruptions in the normal physiology of cell division are almost invariably detrimental. One such type of disruption is cancer, a disease that can arise from a series of genetic events.

Cancer cells are defined by two heritable properties, uncontrolled growth and uncontrolled invasion of normal tissue. A cancerous cell can divide in defiance of the normal growth constraints in a cell leading to a localized growth or tumor. In addition, some cancer cells also gain the ability to migrate away from their initial site and invade other healthy tissues in a patient. It is the combination of these two features that make a cancer cell especially dangerous.

An isolated abnormal cell population that grows uncontrollably will give rise to a tumor or neoplasm. As long as the neoplasm remains in a single location, it is said to be benign, and a complete cure may be expected by removing the mass surgically. A tumor or neoplasm is counted as a cancer if it is malignant, that is, if its cells have the ability to invade surrounding tissue. True malignancy begins when the cells cross the basal lamina and begin to invade the underlying connective tissue. Malignancy occurs when the cells gain the ability to detach from the main tumor mass, enter the bloodstream or lymphatic vessels, and form secondary tumors or metastases at other sites in the body. The more widely a tumor metastasizes, the harder it is to eradicate and treat.

As determined from epidermiological and clinical studies, most cancers develop in slow stages from mildly benign into malignant neoplasms. Malignant cancer usually begins as a benign localized cell population with abnormal growth characteristic called a dysplasia. The abnormal cells acquire abnormal growth characteristics resulting in a neoplasia characterized as a cell population of localized growth and swelling. If untreated, the neoplasia in situ may progress into a malignant neoplasia. Several years, or tens of years may elapse from the first sign of dysplasia to the onset of full blown malignant cancer. This characteristic process is observed in a number of cancers. Prostate cancer provides one of the more clear examples of the progression of normal tissue to benign neoplasm to malignant neoplasm.

The walnut-sized prostate is an encapsulated organ of the mammalian male urogenital system. Located at the base of the bladder, the prostate is partitioned into zones referred to as the central, peripheral and transitional zones, all of which surround the urethra. Histologically, the prostate is a highly microvascularized gland comprising fairly large glandular spaces lined with epithelium which, along with the seminal vesicles, supply the majority of fluid to the male ejaculate. As an endocrine-dependent organ, the prostate responds to both the major male hormone, testosterone, and the major female hormones, estrogen and progesterone. Testicular androgen is considered important for prostate growth and development because, in both humans and other animals, castration leads to prostate atrophy and, in most cases, an absence of any incidence of prostatic carcinoma.

The major neoplastic disorders of the prostate are benign enlargement of the prostate, also called benign prostatic hyperplasia (BPH), and prostatic carcinoma; a type of neoplasia. BPH is very common in men over the age of 50. It is characterized by the presence of a number of large distinct nodules in the periurethral area of the prostate. Although benign and not malignant, these nodules can produce obstruction of the urethra causing nocturia, hesitancy to void, and difficulty in starting and stopping a urine stream upon voiding the bladder. Left untreated, a percentage of these prostate hyperplasia and neoplasias may develop into malignant prostate carcinoma.

In its more aggressive form, transformed prostatic tissues escape from the prostate capsule and metastasize invading locally and throughout the bloodstream and lymphatic system. Metastasis, defined as tumor implants which are discontinuous with the primary tumor, can occur through direct seeding, lymphatic spread and hematogenous spread. All three routes have been found to occur with prostatic carcinoma. Local invasions typically involve the seminal vesicles, the base of the urinary bladder, and the urethra. Direct seeding occurs when a malignant neoplasm penetrates a natural open field such as the peritoneal, pleural or pericardial cavities. Cells seed along the surfaces of various organs and tissues within the cavity or can simply fill the cavity spaces. Hematogenous spread is typical of sarcomas and carcinomas. Hematogenous spread of prostatic carcinoma occurs primarily to the bones, but can include massive visceral invasion as well. It has been estimated that about 60% of newly diagnosed prostate cancer patients will have metastases at the time of initial diagnosis.

Surgery or radiotherapy is the treatment of choice for early prostatic neoplasia. Surgery involves complete removal of the entire prostate (radical prostatectomy), and often removal of the surrounding lymph nodes, lymphadenectomy. Radiotherapy, occasionally used as adjuvant therapy, may be either external or interstitial using 125I. Endocrine therapy is the treatment of choice for more advanced forms. The aim of this therapy is to deprive the prostate cells, and presumably the transformed prostate cells as well, of testosterone. This is accomplished by orchiectomy (castration) or administration of estrogens or synthetic hormones which are agonists of luteinizing hormone-releasing hormone. These cellular messengers directly inhibit testicular and organ synthesis and suppress luteinizing hormone secretion which in turn leads to reduced testosterone secretion by the testes. Despite the advances made in achieving a pharmacologic orchiectomy, the survival rates for those with late stage carcinomas are rather bleak.

SUMMARY OF THE INVENTION

The present invention overcomes the problems and disadvantages associated with current strategies and designs and provides new methods for the identification of sequences related to metastasis.

One embodiment of the invention is directed to methods for the identification of a metastatic sequence. One or more oncogenic sequences are transfected into a cell to form a transfected cell. The transfected cell is introduced into a primary site of a host animal to establish a colony which is incubated in the animal for a period of time sufficient to develop both a primary tumor and a metastatic tumor. Expressed sequences are harvested from the primary tumor and the metastasis. Harvested sequences are compared to each other and to non-metastatic cells to identify sequences related to metastasis. Dominant metastatic genes are genes whose expression leads to metastasis. Such genes are typically expressed at high levels in metastatic cells and not significantly expressed in normal or nonmetastatic cells. Recessive metastatic genes, genes whose expression prevents metastasis, may be selectively expressed in normal and nonmetastatic cells and absent in metastatic cells. Dominant and recessive metastatic genes may act directly or act pleiotropically by enhancing or inhibiting the expression or function of other dominant and recessive metastatic genes.

Another embodiment of the invention is directed to methods for identifying metastatic sequences. A mammalian cell is treated with a metastatic agent and the treated cell is implanted into a primary site of a host mammal. The host animal is maintained for a period of time sufficient for the cells to proliferate and to develop a metastatsis metastasis at a secondary cite site. Expressed squences from cells of the primary cite and cells of the secondary site are reverse transcribed into cDNA by differential display polymerase chain reaction to identify differentially expressed sequences.

Another embodiment of the invention is directed to sequences isolated by the methods of the invention. Sequences may be in the form of DNA, RNA or PNA. The nucleic acid may be single-stranded or double-stranded. Single stranded nucleic acid may be in the form of a sense strand or an antisense strand. In addition, the sequence may be part of a homologous recombination vector designed to recombine with another metastatic sequence.

Another embodiment of the invention is directed to a method for treating a neoplastic disorder comprising administering a pharmaceutically effective amount of a metastatic nucleic acid to a patient. The nucleic acid may be single-stranded in the sense or the antisense direction. Alternatively, the nucleic acid may be packaged in a viral vector such as, for example, a retroviral, a vaccinia or an adenoviral vector. Administration may be performed by injection, pulmonary absorption, topical application or delayed release of the nucleic acid along with a pharmaceutically acceptable carrier such as water, alcohols, salts, oils, fatty acids, saccharides, polysaccharides and combinations thereof.

Another embodiment of the invention is directed to a kit for detecting of the presence or absence of a metastatic sequence.

Other objects and advantages of the invention are set forth in part in the description which follows, and in part, will be obvious from this description, or may be learned from the practice of the invention.

DESCRIPTION OF THE DRAWINGS

FIG. 1 Schematic showing two paths in the multistep progression to cancer.

FIG. 2 A-B Staining of primary tumor (A) and metastatic deposit (B) from the lung of the same animal

FIG. 3 A-D Staining of normal human prostate (A), moderately differentiated human prostate tumor (B and C), and poorly differentiated prostate tumor (D).

FIG. 4 Schematic of method for isolating a metastatic gene from a gene ablated mouse strain.

FIG. 5 A-B Schematic showing method to establish a tumor and a metastatic transplant from fetal tissue(A) and from cell lines and tumors (b).

FIG. 6 Isolation and characterization of nmb gene expression by DD-PCR and RNA blot in primary and metastatic cells.

FIG. 7 Differential expression of multiple genes is determined by DD-PCR and RNA blot of primary and metastatic cells.

FIG. 8 Caveolin identified as a differentially expressed gene by DD-PCR.

FIG. 9 Differential expression of genes isolated by DD-PCR confirmed by RNA blots.

FIG. 10 RNA blot analysis of total tumor mRNA using clone 29 GADPH probes.

FIG. 11 RNA blot of three independent MPR metastatic tumors and 5 MPR non-metastatic tumors.

FIG. A-RR 12 Nucleotide sequences of metastatic nucleic acids.

FIG. 13 A-D Characterization of metastatic sequences isolated.

FIG. 14 Immunohistological staining of primary and metastatic human prostate tumors using anti-caveolin antibodies.

DESCRIPTION OF THE INVENTION

As embodied and broadly described herein, the present invention is directed to methods for identifying metastatic sequences, to the metastatic sequences identified, to methods for the detection, diagnosis and treatment of disorders related to metastasis, and to diagnostic kits which comprise these sequences.

The ability of cancers to metastasize makes tumors difficult to eradicate by any means. Malignant cancer involves a multistage progression from, for example, normal tissue through hyperplasia, early adenoma, early carcinoma and finally to a metastatic tumor (FIG. 1). Cells of a typical tumor loosen their adhesion to their original cellular neighbors and cross the basal lamina and endothelial lining to enter the body's circulation. Once in circulation, the metastatic cell exits from the circulation to disseminate throughout the body and proliferate in a new environment.

Like the initial oncogenic event, the ability of a cell to metastasize requires additional mutationic or epigenetic changes. An understanding of the molecular mechanisms of metastasis allow for the design of treatments to inhibit metastasis. Knowledge of stage specific gene expression for neoplastic disorders allows for early detection and typing of tumors. With early detection and typing, proper treatment may be administered to a patient with the neoplastic disorder earlier, which will lead to a higher probability of a complete cure.

For human prostate tumors, the study of stage specific tumors is difficult, if not impossible, as cell lines are extremely difficult to grow and it is rare that tissue becomes available from the primary tumor as well as metastatic disease from the same patient. This problem is exacerbated because of the infrequent biopsy of metastatic deposits in conjuntion with isolation of material from the primary tumor. Furthermore, the growth of cell lines from malignant prostates has proved to be problematic over the last few decades. This is evidenced by the lack of cell lines from prostate cancer obtained under any conditions.

One embodiment of the invention is directed to a method for identifying a metastatic sequence. A mammalian cell is transformed into a pre-neoplastic or neoplastic state or phenotype by transfection with one or more oncogenic sequences. Alternatively, or in addition to transfection, the mammalian cell may be treated with an agent or subjected to a condition that potentiates the metastatic character of the cell or predisposes the cell to metastasis. The transfected or treated cell is implanted into a host animal at a primary site and grown for a period of time sufficient to develop a metastasis at a secondary site. Expressed sequences from cells of the primary site and cells at the secondary site are amplified by differential display polymerase chain reactions. PCR products from these reactions are compared and the metastatic sequence identified by alteration in the levels or patterns of the resulting products.

Mammalian cells from a wide variety of tissue types and species are suitable for transfection or treatment including surgically obtained or primary or immortalized cells and cell lines. Cells may be from humans or primates, mice, rats, sheep, cows, rabbits, horses, pigs or guinea pigs or from transgenic or xenogeneic host mammals. Cells may be obtained from adult, juvenile or fetal tissue, and used directly from the mammal, from cryogenically preserved samples, or after culturing in vitro or in vivo for a period of time. In vitro culturing typically involves tissue culture conditions (e.g. 37° C.; 5% CO2) while in vivo culturing may involve successive passage of cells through host animals such as, for example, mice or rabbits. Cells passed in vivo may be obtained from sites proximal or distal to the site of implantation. The tissue type from which the cells are derived or obtained may be any tissue which is susceptible to transfection or other treatment including, for example, urogenital tissues, epithelial cells, hepatic cells, fibroblasts lymphatic tissues, hematopoietic cells, cells of the immune system, cells of the gastrointestinal system and cells of the nervous system.

Cell types useful for the identification of metastatic sequences related to prostate cancer include cells and cell lines of the fetal prostate lineage from normal or transgenic animals, and cells from normal or reconstituted prostate tissue. One method of generating reconstituted prostate cells is to isolate fetal prostate tissue and microdissect the fetal prostate epithelium away from fetal mesenchyme. Fetal prostate epithelium may be genetically manipulated before reassociation with fetal mesenchyme (FIG. 5A). Genetic manipulation involves treatment or transfection with a metastatic agent or a nucleic acid sequence that affects neoplastic or metastatic potential of the cell. Reassociation of fetal epithelium and mesenchyme is performed by implanting epithelial tissue within a pocket of mesenchymal tissue. After manipulation, cells are reimplanted into a mammalian host in a similar manner as other cells, such as reimplantation into or under the renal capsule.

Mammalian cells may be transfected by a variety of techniques, all of which are well-known to those of ordinary skill. Direct methods involve the introduction of genetic material into the nucleus of a cell by injection. These techniques include high velocity projectile injection, microinjection, and electroporation. Indirect methods, involving the active or passive uptake of the genetic information by the cell, include transduction with recombinant vectors, and chemical or physical treatments such as calcium phosphate uptake, lipofection or dextran sulfate transfection. Chemical techniques rely on chemical carriers to introduce nucleic acids into a cell. These methods, for example, utilize unilamellar phospholipid vesicles (e.g. liposomes) loaded with DNA (or RNA). The approach relies on the fusion of the DNA containing vesicles with the plasma membrane of the recipient cells. After entry, DNA traverse the cytoplasm and enter the nucleus. Another lipofection technique uses a synthetic cationic lipid such as N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA). DOTMA spontaneously associates with nucleic acids and forms unilamellar vesicles upon sonication. Genetic material is incorporated into these vesicles and subsequently transfected into the cell. Calcium phosphate co-precipitation involves mixing of purified nucleic acid with buffers containing phosphate and calcium chloride which results in the formation of a fine precipitate. Presentation of this precipitate to cells results in incorporation of the nucleic acid into cellular genome. Other chemicals, such as DEAE dextran or polybrene, when present in media with nucleic acids, can also cause the transfection of mammalian cells.

Physical methods of transfection rely on electric fields, needles and particles to enable nucleic acids to traverse the cellular membrane. Electric field mediated DNA transfection, commonly called electroporation, is based on the principle that membranes, when subjected to an electric field, undergo a reversible breakdown resulting in pores large enough to permit the passage of nucleic acids. In micro-projectile mediated gene transfer, micro-projectiles of subcellular dimensions are coated with nucleic acid and propelled at high velocity into a cell using a particle gun. The nucleic acid is introduced into the nucleus directly when the particles impinge upon the nucleus. In microinjection, nucleic acid is injected directly into the nucleus of a cell with a needle. Lasers have also been used to introduce minute holes in cellular membrane to allow introduction of nucleic acids. All these methods may be used for transfection and the selection of the method will depend on the cell type, the desired transfection efficiency and the equipment available.

The efficiency of transfection may be monitored and enhanced by the co-transfection of a selectable marker. If a marker is co-transfected with a genetic construct, positively transformed cells may be separated from nontransformed cells by chemical selection. The efficiency of transfection will be increased in most cases because the chemicals will selectively kill non-transfected cells. The number of transfected cells may also be monitored by analyzing the degree of chemical resistance of the transfected cells. Markers commonly used for selection purposes include, for example, nucleic acids encoding dihydrofolate reductase, metallothionein, CAD, adenosine deaminase, adenylate deaminase, UMP synthetase, IMP 5′-dehydrogenase, xanthine-guanine phosphoribosyltransferase, mutant thymidine kinase, mutant HGPRTase, thymi dylate synthetase, P-glycoprotein 170, ribonucleotide reductase, glutamine synthetase, asparagine synthetase, arginosuccinate synthetase, ornithine decarboxylase, HMG-CoA reductase, N-acetylglucosaminyl transferase, theronyl-tRNA synthetase, sodium or potassium dependent ATPase or derivatives or mutants of these nucleic acids. Markers may be used individually or in combination. Chemicals useful for selection include methotrexate, cadmium, PALA, Xyl-A, adenosine, 2′-deoxycoformycin, adenine, azaserine, coformycin, 6-azauridine, pyrazofuran, mycophenolic acid, limiting xanthine, hypoxanthine, aminopterin, thymidine, 5-fluorodeoxyuridine, adriamycin, vincristine, colchicine, actinomycin D, puromycin, cytocholasin B, emetine, maytansine, Bakers' antifolate, aphidicolin, methionine sulfoximine, &bgr;-aspartyl hydroxamate, albizziin, canavanine, &agr;-difluoromethylornithine, compactin, tunicamycin, borrelidin, ouabain, and derivatives and analogs and combinations of these chemicals. Some chemicals, such as methotrexate, may be used individually while other chemicals, such as HAT (hypoxanthine, aminopterin and thymidine), need to be used in combination to be effective.

The oncogene transfection efficiency, the fraction of live cells tranfected by an oncogene, may be indirectly enhanced by chemical selection for a co-transfected marker. An oncogene is a sequence which can predispose, or induce the cell into a pre-neoplastic or neoplastic condition or otherwise enhance the metastatic potential of the cell. Sequences with these properties are referred to as oncogenes and include abl, ahi, akt, bcl, crk, dsi, erb, ets, evi, fes/fps, fim, fis, fgr, flv, fms, fos, gin, gli, int, jun, kit, mas, lck, met, mil/raf, mis, mlv, mos, myb, myc, neu, onc, pim, raf ras, rel, ros, seq, sis, ski, spi, src, tcl, thy, trk, and yes. Some oncogenes, such as ras, are oncogenic when mutated. Other oncogenes, such as myc, are oncogenic when overexpressed or underexpressed. Many oncogenes represent members of multigene families or homologs families. Homologs are proteins that have similar primary, secondary or tertiary structures. Genes may differ in nucleic acid sequence or encoded peptide sequence and still be homologs when the encoded polypeptides have similar spatial folding. Many oncogenes can be classified into dominant oncogenes and recessive oncogenes. One or more dominant oncogenes can confer a neoplastic or pre-neoplastic phenotype to a cell. One or more recessive oncogenes, when silenced, may also confer a neoplastic or preneoplastic phenotype. Gene silencing is performed by transfecting cells with nucleic acids which cause genetic ablation or by antisense suppression.

While any oncogene may be used, the preferred oncogenes are those that are normally associated with metastasis such as a metastasis specific gene. Such genes include for example, TGF-&bgr;1, Cyclin D1 p21, p34, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb or &agr;-actinin 3. Metastatic-specific genes may be used individually or in combination with other oncogenes.

The metastatic potential of a cell may be altered, for example, by gene ablation with of a sequence specific for a recessive oncogene. Recessive oncogenes are those genes which encode products which can suppress oncogenesis and metastasis. A gene ablation sequence can be designed to specifically suppress a recessive oncogene. Ablation may include pre-transcriptional inhibition such as homologous recombination with endogenous recessive oncogenes and post transcriptional inhibition such as the expression of antisense oncogenes to suppress translation. Gene ablation sequences may be targeted towards well known recessive oncogenes such as, for example, the retinoblastoma gene (Rb) or Bcg Bcl. Other candidates for ablation include metastatic genes previously isolated by the invention such as, for example, TGF-&bgr;1, cyclin D1, p21, p34, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb or &agr;-actinin-3. The effects of ablating a recessive oncogene may include oncogenesis and metastases.

Alternatively, or in addition to transfection the mammalian cell may be treated with an agent, either before or after transfection, that alters the expression of the cell's nucleic acids. Treatment may comprise contacting the cells with one or more agents which affect the neoplastic predisposition (e.g. neoplastic agents; phorbol esters), metabolization (e.g. metabolic agents), metastasis (e.g. metastatic agents), differentiation (e.g. differentiation agents; retinoic acid), activation or proliferation (e.g. growth factors) of the cell. Agents which can alter gene expression include chemicals such as benzanthracene (BA), dimethyl benzanthracene (DMBA) or 5-azacytidine. Alternatively, treatment may also comprise altered conditions such as hypoxia which involves subjecting a cell to a reduced oxygen content, exposable to radiation or other stresses to the cell.

Treatment may be in vitro or in vivo and may include for example, direct or indirect induction or suppression of well known oncogenic sequences and genes isolated by the invention such as, for example, TGF-&bgr;1, Cyclin D1, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb, &agr; actinin 3, and p34. Gene expression induction includes transfecting expression vectors encompassing coding regions of the gene. Gene repression comprises introducing a gene ablation sequence or a repressor of the gene to the cell.

Cells which have one or more genes ablated may also be used. For example, a metastatic suppressor gene may be ablated to prevent inhibition to metastases. A useful gene for ablation is a gene capable of affecting the phenotype and behavior of a cell or tumor. For example, with prostate tumors, suitable genes include both well known genes and genes isolated by the methods of the invention such as for example, TGF-&bgr;1, Cyclin D1, p21, p34, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb and &agr; actinin 3. Genetic ablation (gene knockout) refers to a process of silencing the expression of a particular gene in a cell. The silencing process may include, for example, gene targeting or antisense blocking. Gene targeting refers to a process of introducing a nucleic acid construct into a cell to specifically recombine with a target gene. The nucleic acid construct inactivates the targeted gene. Inactivation may be by introduction of termination codons into a coding region or introduction of a repression site into a regulatory sequence. Antisense blocking refers to the incorporation into a cell of expression sequences which directs the synthesis of antisense RNA to block expression of a target gene. Antisense RNA hybridizes to the mRNA of the target gene to inhibit expression.

The host animal is preferably the same species as the implanted cell. In cases of xenogeneic transplants, the host may be immunocompromised genetically or by treatment with drugs such as immunosuppressants. A host may be immunocompromised genetically by breeding such as with nude mice or severe combined immunodeficient (SCID) mice. A host may also be immunocompromised by chemical or irradiation methods. An additional route to immunocompromise a host is to use transgenic technology to introduce an immunosuppressing gene or to introduce a foreign antigen gene. An immunosuppressing gene is a gene that affects the efficiency of the immune system such as a gene which inhibits the formation of cells of the B cell or T cell lineage. A foreign antigen gene, when expressed, may cause the host to tolerate the antigens in a xenogeneic transplant and not mount an immune response.

Cells may be implanted into any primary site in a host animal, such as, for example, subcutaneous implantation, intravenous injection, or implantation into the abdominal cardiac, chest, pulmonary, thoracic or peritoneal cavity. Using techniques known to those of ordinary skill in the art, cells can be placed on or in nearly any organ or tissue. Reasons for choosing a site include ease of implant, proximity of similar tissue type, immunoprivileged position and ease of inspection. Metastasises migrate from the primary site to one or more secondary sites such as, for example, the lung, kidney, liver, lymph nodes, brain, testis, bone, spleen, ovaries or mammary. Preferred sites include the renal capsule, the testes, the prostate and the ovaries.

To avoid histocompatibility problems, the implant may be placed into a histocompatible host animal. Such problems are generally avoided if the implant and host animal are syngeneic. Alternatively, a non-histocompatible host may be used if the host can be made immunotolerant. Hosts may also be transgenic or immunocompromised animals or genetically matched to the mammalian cells to be introduced. Immunocompromised animals may be derived from established mouse lines such as nude mice or severe combined immune deficiency (SCID) mice, or by treatments such as radiation, chemical, pharmaceutical or genetic targeting. Sufficiently immunosuppressed animals can be made tolerant to xenogeneic transplants.

After implantation the host animal is maintained under normal conditions to develop metastases. Alternatively, the host animal may be subjected to an altered treatment or environmental condition to stimulate or repress metastasis or induce other cellular functions. In metastasis, a sub-population of cells of the implantation site invade and establish one or more secondary colonies in the host animal. The behavior of the implanted cell will depend on the cell type, the transfected sequence and the implantation location. Typical secondary sites for metastatic colonies include lung, kidney, liver, lymph nodes, brain, testis, spleen, bone, ovary, skin and mammary tissue. Metastatic development times vary from days to weeks even months. Cells with a high metastatic potential tend to progress to metastasis quickly while cells with a low metastatic potential may require very long periods of time that span significant portions of the lifespan of the animal.

The host animal may be analyzed for metastatic development weekly, from one week to 20 weeks to six months, nine months or one year after implantation. For animals with longer lifespans such as sheep, the animal may be inspected yearly from one year on up to ten years for metastatic tumors. Metastases can be detected by examinations such as palpation, biopsy, imaging, exploratory surgery, CAT scans, autopsy, X-ray and direct observation. In addition, tissue samples may be taken surgically from the host mammal and subjected to histological or other examination for the detection of metastases.

Expressed sequences include mRNA, rRNA, hnRNA, DNA, cDNA and any nucleic acid sequence that is expressed in the cell. These sequences may be amplified by in situ techniques or by purification of nucleic acid from collected cells. Expressed sequences may be obtained by extracting nucleic acids from cells before implantation, at the primary site or at the secondary site. Cells collected at these sites may optionally be cultured for a time before nucleic acid extraction. The effects of treatment with gene expression modifying agents or environmental conditions can be ascertained by collecting cells before and after treatment. Treatment may be applied to the cells while the cells are in the host mammal or after the cells are excised and in culture. Nucleic acid are collected from cells using techniques that are well known to those of ordinary skill in the art.

Expressed sequences may be used directly for polymerase chain reaction (PCR) analysis using, for example, the technique of reverse transcriptase polymerase chain reaction (RT-PCR). Alternatively, RNA may be enriched for mRNA using a poly-A RNA enrichment method. Numerous poly-A RNA enrichment methods exist and are commercially available. Techniques used for poly-A RNA enrichment include oligo-dT columns, oligo-dT magnetic beads, and oligo-dT cellulose. RNA may be further processed into cDNA before analysis by reverse transcription using reverse transcriptase. The cells or the extracted nucleic acid may be preserved, such as by freezing, and analyzed at a later time.

Differential display polymerase chain reactions (DD-PCR) are performed on the expressed sequences using two variable primers which may contain the same or entirely different sequences or an anchor primer and a variable primer. If an anchor primer is used, one anchor primer and one variable primer create a single or a single set of reaction products for each reaction. A complete profile may include 25 or more different PCR reactions per sample wherein each PCR reaction is performed with the same anchor primer and a different variable primer. DD-PCR may also be performed using anchor and variable primers which contain the same sequence. Whether a particular reaction is used depends on whether a difference exists between the products of two PCR reactions using the same primers. When a significant difference exists between the expression sequences amplified, one pair of PCR reactions may be sufficient and informative.

Anchor primers are preferably oligonucleotides with a poly-T sequence at the 5′-terminas terminals and a dinucleotide selected from the group consisting of AA, AG, AC, AT, GA, GG, GC, GT, CA, CG, CC and CT at the 3′-terminas terminals. For example, the sequence may be 5′-TTTTTTAA-3′ or 5′-TTTTTTAG-3′. The length of the poly-T sequence is typically between about 5 to about 30 bases in length and preferably between about 10 to about 20 nucleotides long. The total length of the anchor primer can vary greatly for each experiment but is preferably between about 7 to about 32 and more preferably between about 12 and about 22. Differential diagnostic display polymerase chain reaction may also be performed using an anchor primer of any sequence and a length between about 5 to about 30, preferably between about 5 to about 20 and more preferably between about 7 to about 12 bases.

The variable primer may comprise a random sequence, or a specific sequence such as, for example, a sequence of SEQ ID NO. 1 to SEQ ID NO. 24. Variable primers preferably are oligonucleotides with a length between about 5 to about 30, preferably between about 5 to about 20, and more preferably between about 7 to about 12 bases in length.

To enhance detection of the PCR product, the anchor primer or the variable primer, or both, may comprise a detectable moiety. Examples of detectable moieties include radioactive moieties, phosphorescent moieties, magnetic moieties, luminescent moieties, conjugatable moieties or other detectable moiety. A plurality of detectable moieties may be used to enhance detection or to simplify data analysis. Other detectable moieties include conjugatable moieties and molecules which can bind specifically to other molecules which are themselves detectable. Examples of conjugatable moieties include avidin, streptavidin, biotin, antibody, antigen, cell adhesion molecules and other molecules with similar activities. Detectable moieties are preferably labeled nucleotides. A nucleotide may be any natural or synthetic nucleotide or nucleotide analog capable of incorporation into an elongation reaction in a polymerase chain reaction. Labeled nucleotides include nucleotide triphosphates labeled with one or more radioactive atoms such as 32P, 33P, 3H, 14C and 35S. Products of DD-PCR reactions are compared to detect the metastatic sequence. Comparisons can be performed between expressed sequences from cells at secondary sites with cells at any stage in the method including untreated mammalian cells, transfected or treated manmmalian cells, implanted cells or cells obtained from the primary site in the host animal. DD-PCR products may be analyzed by any method which reliably compares the products of two polymerase chain reactions. Typical analytical methods used for this purpose include polyacrylamide gel electrophoresis, capillary electrophoresis and high pressure liquid chromatography (HPLC). Product produced from DD-PCR may be analyzed in double-stranded or single-stranded forms. When the products of the DD-PCR reaction are labeled the sizes and distribution of the products may be monitored and analyzed by following the labels using a radiation monitor or by autoradiography. For example, DD-PCR performed in the presence of radioactive primers or nucleotide triphosphates, can be analyzed by gel electrophoresis, by capillary electrophoresis, or by HPLC. Products are easily monitored by the presence of radioactivity.

Another method for analyzing and isolating metastatic sequences is to sequence the amplified nucleic acid sequences. Sequencing may be performed using standard methods well known to those of ordinary skill in the art. The resulting sequence may be compared to a sequence database created or well-known, such as Genbank, for identification or for locating homologs. The sequencing information may be used to calculate the physical characteristics of the nucleic acids such as melting temperature and secondary structure. The primary sequence and the physical characteristic may be used to synthesize optimal nucleic acid probes for the detection or staging of metastasis or conditions that are predictive of the presence or absence of the metastatic condition.

Another embodiment of the invention is directed to a method for identifying a metastatic sequence. A mammalian cell is pretreated with a metastatic agent to form a population of cells predisposed to metastasize. The treated cells are introduced into a host mammal at a primary site. The host animal is maintained for a period of time sufficient to develop a metastasis at a secondary site. Expressed sequences of cells at the primary site and cells at the secondary site are treated with a genotoxic agent or subjected to genotoxic conditions. Expressed sequences of the treated cells are amplified by differential display polymerase chain reaction and compared with untreated cells from any previous step to identify the metastasis sequence.

The metastatic agent may be a chemical compound, a nucleic acid or a protein that alters the metastatic potential of a cell or relates to or is associated with the metastatic process. Chemical compounds include retinoids such as 4-hydroxyphenyl (4HP). Other agents include the proteins TGF-&bgr;1, Cyclin D1, p21, p34, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb or &agr;-actinin 3, or their respective genes. The metastatic agent may be a metastatic stimulant or a metastatic suppressant. Metastatic stimulants may be used to enhance the sensitivity of the metastasis sequence detection method. Conversely metastatic suppressants may be used to decrease the sensitivity of the method enabling the selective identification of potent metastatis metastatic sequences or sequences specific to a particular tissue type or detastatic disorder. Treatment may comprise direct contact with the metastatic agent or incubation for a period of time. Metastatic agents enhance the metastatic potential of the implanted cells and increase the sensitivity and the speed of the overall method.

The cells at the primary site and the metastatic cells at the secondary site may be treated with a genotoxic agent in vivo or in vitro. In vivo treatment may comprise injecting genotoxic agents directly into the host mammal or specifically applying the agent with, for example, topical formulations. The cells at the primary site and the secondary site may also be isolated from the host animal and treated with the genotoxic agent in culture. Genotoxic agents are chemical compounds, nucleic acids or proteins that alter gene expression by effecting the nucleic acid genome directly by, for example, chemical modification, or indirectly by, for example, altering components associated with gene expression. Such agents include, for example, benzanthracene (BA), dimethyl benzanthracene (DMBA) and 5-azacytidine, and may include metastatic agents as well. In addition to or in place of genotoxic agents, the cells may be treated to hypoxic conditions or radiation to alter gene expression. Metastatic sequences identified in these methods may be specific for particular genotoxic agents or conditions.

Another embodiment of the invention is directed to the use of a host animal with an altered genotypic or phenotypic predisposition for metastases. A host animal may be screened for endogenous expression of metastases gene. Examples of metastatic sequences which may be screened for include sequences isolated by the method of the invention, such as, for example, the sequences listed in FIG. 12 and FIG. 13. Particularly useful metastatic sequences include TGF-.beta.. A host animal with reduced levels of a metastatic gene product may be used to isolate novel metastatic genes. Host animals may be screened for reduced levels of metastatic gene expression. In addition, transgenic technology may be use to ablate a metastatic gene in the germline of a host animal.

Another embodiment of the invention is directed to analysis of a cell line before their use as a starting material to isolate metastatic genes in a particular pathway. Analysis is useful in identifying cells, and consequently sequences specific to these cells, which are particularly susceptible or resistant to metastatic transformation. For example, a cell highly predisposed to metastasis may be especially sensitive for detecting metastatic genes. Conversely, a cell showing high resistance to metastasis can be used to isolate especially potent metastatic sequences. One method to analyze susceptibility to metastasis is to determine the cellular response to growth factors or growth inhibitors. Briefly, a control population and a test population of cells are exposed to a growth factor or a growth inhibitor and the cellular response (e.g. proliferation, metabolism) recorded. Cells showing abnormal responses to the growth factor or growth inhibitor may be used as the starting material for metastatic gene isolation. Cellular response include changes in the rate of cellular division (e.g. thymidine uptake), changes in the expression of RNA or proteins, changes in cellular localization or modification patterns of RNA or proteins, and changes in the rate of uptake, release or metabolism of nutrients.

Especially potent or weak metastatic genes may be detected by treating and analyzing the metastatic potential of different cells and selecting a suitable cell type as the starting material. For example, cells may be treated with myc, ras, mutant p53 or combinations thereof and analyzed for cyclin D1 expression which is shown to correlates correlate with metastasis. FIG. 2 shows the in situ analysis of cyclin D1 in primary MPR tumors (FIG. 2A) and in metastatic deposits from the lung of the same animal (FIG. 2B). The gene expression pattern of cyclin D1 in MPR correlates with that of human prostate tumors (FIG. 3) analyzed with stains specific for cyclin D1 expression. Normal human tissue shows no cyclin D1 expression or staining (FIG. 3A). Moderately differentiated prostate cancers with dispersed (FIG. 3B) or focal positively staining (FIG. 3C) show moderate staining. Advanced poorly differentiated prostate cancer cells show strong nuclear as well as cytoplasmic staining (FIG. 3D) implying strong expression of cyclin D1. After treatment with myc, ras or mutant p53, cyclin D1 expression shows correlation with the metastatic potential of the cell. Thus, cyclin D1 expressing cells are a source of cells with high metastatic potential. Conversely, cells with low cyclin D1 expression are a source of potentially metastatically metastasis resistant cells.

This method may be adjusted for the isolation of metastatic sequences expressed along a particular developmental or differentiation pathway by combining the various treatment and analytical techniques. This approach is schematically represented in FIG. 4. For example, a mammalian cell may be genetically ablated for TGF-&bgr;6, Cyclin D1, mutant p53, lysyl oxidase, caveolin, actin binding protein, ubiquitin activating enzyme E1, nmb, &agr; actinin 3, or p34. The genetically altered cell is used in an in vivo mouse prostate reconstitution (MPR) model. Metastatic and nonmetastatic cells isolated from the MPR may be analyzed directly or after induction with an agent such as the TGF-&bgr; gene or its product. Analysis involves the use of differential display polymerase chain reaction to identify differentially expressed bands. Sequences identified may be used for subsequent ablation, transformation or differential analysis.

Genetic ablation (gene knockout) may be performed after a cell is selected or by selecting a cell comprising a genotype with the proper genetic ablation. Cells already comprising gene ablation may be acquired from a cell depository, from other laboratories or from a transgenic animal. As transgenic animals comprise genetically ablated genes in every cell, any tissue from a transgenic animal may be used as the starting material.

The effects of oncogenes are at least additive and often synergistic. Thus, dominant oncogenes may be transfected together or multiple recessive oncogenes ablated together for a stronger effect. Furthermore, both methods may be combined and dominant oncogene transfection may be accompanied by recessive oncogene ablation.

The function of the metastatic sequence may be determined by the differential expression pattern. For example, a dominate dominant metastatic gene will be present in a metastatic cell while a recessive metastatic gene is present in a non-metastatic cell. Metastatic sequences may be detected as bands which are present in the DD-PCR of metastases isolated in secondary sites and yet absent from DD-PCR products of primary cells. These sequences may be dominant metastatic genes whose expression is directly responsible for metastases, or they may be metastasis associated genes whose expression correlates with metastasis. Either are useful for therapy and diagnosis. Conversely, DD-PCR bands which are present in primary site tumors, but absent in secondary metastatic sites, may be dominant metastasis suppression genes. Dominant metastasis suppression genes comprise genes whose expression suppresses metastasis while nonmetastatic genes comprise genes whose expression correlates with non-metastatic tissue. Genes which are highly correlative with either the metastatic phenotype or the non-metastatic phenotype may be isolated. Isolation can be performed by cutting the appropriate nucleic acid in the containing band of from a polyacrylamide gel or by collecting the appropriate fraction in an HPLC or capillary electrophoresis. The nucleic acid may be cloned into a plasmid vector, and sequenced, or synthetically prepared.

Another embodiment of the invention is directed to a method for identifying sequences in a metastatic pathway which are responsive or unresponsive to extracellular signals. Such sequences may be used in therapy and diagnosis of metastatic disorders. Implanted cells or cells from a primary site and cells from a secondary site are treated with extracellular signals. RNA sequences from the treated cells are compared with RNA sequences of the untreated cells (FIG. 5B). Treated cells and untreated cells may be derived from a short term or long term in vitro culture of primary tumors and malignant tumors. Alternatively, a part of a primary tumor and a part of a malignant tumor may be collected before the animal is treated with an extracellular cytokine or other factor. Long term cultures, or cell lines of primary and malignant cells may also be used as recipients of extracellular growth signal treatment. Suitable signals for each experiment will depend on the cell type. Generally, growth factors, lymphokines, inhibitory factors, migratory factors or hormones may be used. Factors previously isolated by commercial or methods of the invention and factors associated with or causative or suppressive of metastasis are preferred. Thus, transforming growth factor &bgr;1 (TFG-&bgr;1) may be used to treat cells before DD-PCR analysis. Proteins encoded by the genes isolated by this method are especially useful for the treatment of cells for the isolation of additional sequences. The identification of one sequence responsive to the extracellular signal pathway allows for identification of additional genes upstream and downstream from that sequence.

Another embodiment of the invention is directed to metastatic sequences identified by the methods of the invention. Metastatic sequences are sequences associated with the presence or absence of a metastasis or related to the metastatic process can be used in the therapeutic treatment of metastasis. Metastatic-related sequences include dominant metastatic sequences, recessive metastatic sequences, metastasis associated sequences, dominant oncogenes, recessive oncogenes and cell cycle genes. These genes encode for example, proteins involved in cell cycle, signal processing, DNA replication, growth regulation, inter and intra cellular signaling transcription control and translation control. Isolated sequences are useful in the treatment and for the detection of metastatic and other disorders. Disorders which may be treated comprise diseases involving proteins and sequences which are isolated by interaction with the sequences and proteins isolated by the method of the invention. Both malignant or nonmalignant disorders may be treated. Non malignant disorders include hyperplasia, dysplasia and hypertrophy. Examples of nonmalignant disorders include benign enlargement of the prostate, nodular hyperplasia, and benign prostatic hypertrophy.

Treatment may involve gene replacement, gene targeting, antisense inhibition, gene expression or gene suppression. Gene replacement involves replacing a copy of a defective gene with another copy by homologous recombination. Gene targeting involves the disruption of a cellular copy of a gene by homologous recombination. Antisense inhibition exploits the specificity of hybridization reactions between two complementary nucleic acid chains to suppress gene expression. Cloned genes can be engineered to express RNA from only one or the other DNA strands. The resultant RNA hybridizes to the sense RNA and inhibits gene expression. Gene expression and gene suppression involve the introduction of genes whose expression actively inhibits neoplastic transformation and metastasis.

Another embodiment of the invention is directed to nucleic acids which comprise a sequence identified by the methods of the invention. The nucleic acid may be DNA, RNA or PNA and may be used as a diagnostic tool in the treatment of neoplastic disorders and malignant tumors. The nucleic acids may comprise additional sequences such as promoters, for expression of a sense or antisense message, recombination sequences for gene targeting, selectable markers for transfections, or replication origins for passage in a prokaryotic or eukaryotic host such as animal cells, bacteria or yeast.

Another embodiment of the invention is directed to nucleic acids which comprise sequences identified by the method of the invention such as, for example, the caveolin gene, ABP280 (actin binding protein 280), the lysyl oxidase gene, and the nmb gene (clone 29), and other sequences listed in FIG. 12 and FIG. 13. Nucleic acids comprising a sequence corresponding to these genes may be used in treatment or diagnosis and in diagnostic kits for screening biological samples for the presence or absence of metastasis or metastatic potential. Treatment may involve using the sequences in gene therapy, including gene ablation, gene expression and antisense suppression. Diagnosis may involve genotypic analysis of samples to determine the existence and expression levels of the expressed sequences.

Another embodiment of the invention is directed to the use of caveolin gene and protein in the isolation of oncogenes and in the treatment of neoplastic disorders such as, for example, prostate cancer. Caveolin is an integral membrane protein and a principal component of caveolae. Caveolae are small invaginations at or near the plasma membrane of most smooth muscle cells and may function as a component of specific signal transduction pathways. Surprisingly, caveolin expression increases in metastatic human prostate cells as compared to human primary prostate tumors.

As caveolin expression correlates with metastasis, application of biological technologies designed to block the activity of caveolin or the function of caveolae may have therapeutic benefits for the treatment of neoplastic disorders such as human prostate tumors. Specific treatment approaches using caveolin may include the delivery of antisense or dominant negative caveolin sequences using expression or viral vectors; as well as the use of specific anti-caveolin antibodies. Additional approaches could also target the cavoeolae, but are not specifically based on caveolin function. Additional protein and non-protein components of caveolae could also be targeted for abrogation or the local or systemic administration of nutritional or biological agent may also be used. For example, caveolae are extremely rich in cholesterol and disruption or depletion of this molecule may alter the function of caveolae.

Another embodiment of the invention is directed to methods for treating a neoplastic disorder comprising administering a pharmaceutically effective amount of composition containing a nucleic acid having a sequence identified according to the methods of this invention, its expression product or fragments of either. The nucleic acid may be in the form of a sense or antisense single-stranded or double-stranded nucleic acid. The composition may be combined with a pharmaceutically acceptable carrier such as water, alcohols, salts, oils, fatty acids, saccharides, polysaccharides administered by injection, pulmonary absorption, topical application or delayed release. More than one carrier may be used together to create a pharmaceutical with desirable properties.

Another embodiment of the invention is directed to a kit or diagnostic acid aid for screening biological samples for detection of metastasis, or neoplasia or kits . Kits comprise sequences isolated according to the methods of the invention and reagents and materials useful in such kits, such as, for example, buffers, salts, preservatives, and carriers, all of which are well known to those of ordinary skill in the art. Kits are useful for the analysis of tissues to screen those for the determination of normal, nonmalignant neoplastic or malignant cells. Kits may comprise additional reagents useful for the extraction of nucleic acids from a tissue sample. Reagents for analyzing the nucleic acid extracted from a tissue sample such as polymerase chain reaction reagents and Southern blots reagents may also be included.

The following experiments are offered to illustrate embodiments of the invention and should not be viewed as limiting the scope of the invention.

EXAMPLES

Example 1

Production of Mouse Prostate Reconstitution Tumors and Metastasis.

Mouse Urogenital Sinus (UGS) tissue was isolated from 17 day old mice embryos. Each isolated UGS was digested with 1% trypsin for three hours at 4° C. The trypsin was inactivated by the addition of fetal calf serum. UGS cells were digested with 0.125% collagenase for 1.5 hours, counted and mixed at the appropriate cell ratios prior to infection with retrovirus in the presence of polybrene. Retroviruses used include Zipras/myc-9. Control experiments were performed using BAGA virus. After a two-hour infection, the infected cells were centrifuged and individual reconstitutions containing 1.5·106 cells produced by resuspending the cells in rat tail collagen at a density of 6.0·107 cells per ml. Aliquots of the infected UGS cells were placed in (DME) with 10% fetal calf serum overnight at 37° C., 5% CO2.

The next morning each cell/collagen reconstitution was implanted under the renal capsule of an adult male +/+ animal. Reconstitutions were harvested from the mice five weeks later when they showed signs of obvious distress from the tumor burden. Metastasized tumors were isolated from the same mice at sites outside the renal capsule. Isolated tumors and metastasises were either stored in liquid nitrogen or in preservatives such as 10% buffered formalin.

Cell lines were derived from fresh tumors by mincing a small portion of the primary and metastatic tumor and placing each in explant culture in Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal calf serum. Cells which grow from each explant were propagated in DMEM and 10% fetal calf serum.

For histological analysis, a portion of a fresh tumor was fixed in 10% buffered formalin and embedded in paraffin for sectioning and staining with hematoxylin and eosin (H&E) or immunohistochemical staining. Immunohistochemical localization of cytokeratins was detected using polyclonal cytokeratin antiserum A575 (Dake Co.; Carpinteria, Calif.) and Vectastain ABC kit (Vector Laboratories; Burlingame, CA).

Example 2

Isolation of C-DNA for DD-PCR.

Total cellular RNA was isolated by ultracentrifugation through cesium chloride. Briefly, up to one gram of cells from culture, tumors or organs was placed into 4 ml of ice-cold GIT buffer (4M guanidine isothiocyanate, 0.025M sodium acetate, 0.1M M &bgr;-mercaptoethanol) and homogenized in a tissue homogenizer (Polytron or equivalent). The homogenate was carefully layered over 4 ml of 5.7M CsCl, 0.024M sodium acetate (1.8 g CsC1 per ml) in a centrifuge tube. The layers were centrifuged at 35,000 RPM for 18 hours in a SW50.1 rotor. DNA was collected from the interface between the cushion and the supernatant, diluted two folds with water, added to 2.5 volumes of ethanol and spooled out on a glass rod. RNA that formed a pellet on the bottom of the CsCl layer was resuspended, and once extracted with an equal volume of phenol:chloroform (1:1), twice with chloroform and precipitated with ethanol and resuspended in diethylpyrocarbonate treated water. The concentration of DNA and RNA were be determined by absorption at 260 nanometers.

Example 3

Differential Display Polymerase Chain Reaction.

mRNA isolated from primary tumors or metastasis was reverse transcribed with one of the primers and subjected to DD-PCR using the same primer as both the forward and reverse primer. A set of 24 primers comprising short oligonucleotides were used for both the reverse transcription of mRNA into c-DNA and for differential display polymerase chain reaction. The sequence of the primers used are shown in Table 1.

TABLE 1 Primer No. Sequence Sequence number 1 5′-TGACAATCG-3′ (SEQ. ID. NO. 1) 2 5′-ACTAAGGTC-3′ (SEQ. ID. NO. 2) 3 5′-TCTGCGATCC-3′ (SEQ. ID. NO. 3) 4 5′-ATACCGTTGC-3′ (SEQ. ID. NO. 4) 5 5′-TACGAAGGTC-3′ (SEQ. ID. NO. 5) 6 5′-TGGATTGGTC-3′ (SEQ. ID. NO. 6) 7 5′-CTTTCTACCC-3′ (SEQ. ID. NO. 7) 8 5′-GGAACCAATC-3′ (SEQ. ID. NO. 8) 9 5′-TGGTAAAGGG-3′ (SEQ. ID. NO. 9) 10 5′-TCGGTCATAG-3′ (SEQ. ID. NO. 10) 11 5′-CTGCTTGATG-3′ (SEQ. ID. NO. 11) 12 5′-GATCAAGTCC-3′ (SEQ. ID. NO. 12) 13 5′-GATCCAGTAC-3′ (SEQ. ID. NO. 13) 14 5′-GATCACGTAC-3′ (SEQ. ID. NO. 14) 15 5′-GATCTGACAC-3′ (SEQ. ID. NO. 15) 16 5′-TTAGCACCTC-3′ (SEQ. ID. NO. 16) 17 5′-ACCTGCATGC-3′ (SEQ. ID. NO. 17) 18 5′-GCTATACTGC-3′ (SEQ. ID. NO. 18) 19 5′-AGTTGCCAGG-3′ (SEQ. ID. NO. 19) 20 5′-AAGCCGTGTC-3′ (SEQ. ID. NO. 20) 21 5′-TCAACGCTCA-3′ (SEQ. ID. NO. 21) 22 5′-TGTTCGAATC-3′ (SEQ. ID. NO. 22) 23 5′-CGAGTCAGAC-3′ (SEQ. ID. NO. 23) 24 5′-TATGAGTCCG-3′ (SEQ. ID. NO. 24)

PCR was performed using standard conditions with 40 cycles of denaturation at 94° C. for 40 seconds, annealing at 40° C. for 2 minutes, and elongation at 72° C. for 35 seconds. After PCR, the products were analyzed with non-denaturing polyacrylamide gel electrophoresis (PAGE) at 12 watts for 15 hours. Bands which differed between test and control samples were eluted from the gel, subjected to reamplification by PCR and cloned. Polyacrylamide gel electrophoresis of DD-PCRs, and the accompanying RNA blot analysis showing the isolation of sequences with substantial similarity to nmb and TGF-&bgr; is shown in FIG. 6 and FIG. 7 respectively. Additional sequences isolated by this method show substantial similarity to lysyl oxidase, actin binding protein, ubiquitin activating enzyme E1, &agr;-actinin, and P34 ribosomal binding protein sequence (FIG. 8). Differential expression of caveolin was demonstrated by DD-PCR followed by PAGE (FIG. 9).

Example 4

p53 Allelotype Determination.

The p53 allelotype of a cell sample was determined by PCR. Briefly, nucleic acid is extracted from a tissue sample or a cell culture sample. An aliquot of nucleic acids in placed in 45 &mgr;l aliquot of a master mix which contained a final concentration of 0.2 mM of each dATP, dTTP, dGTP, dCTP, 1.5 mM MgCl2, 0.5 unit Taq polymerase, 0.05 &mgr;M of each of two primers set specific for the normal wildtype allele of p53 (5′-GTGTTTCATTAGTTCCCCACCTTGAC-3′, SEQ. ID NO. 25; 5′-AGAGCAAGAATAAGTCAGAAGCCG-3′, SEQ. ID NO. 26). A control set of primers specific for the fibroblast growth factor-7 gene was used to monitor the polymerase chain reaction experiment (5′-ACAGACCGTGCTTCCACCTCGTC-3′, SEQ. ID NO. 27; 5′-CCTCATCTCCTGGGTCCCTTTCA-3′, SEQ. ID NO.28). One &mgr;l of the reaction from the first round of PCR was used as the starting material for a second round of PCR using a second set of wildtype p53 specific primer (5′-GTCCGCGCCATGGCCATATA-3′, SEQ. ID NO. 29; 5′-ATGGGAGGCTGCCAGTCCTAACCC-3′, SEQ. ID NO. 30). This second round of PCR was also monitored using a control set of primers specific for the fibroblast growth factor-7 (5′-ACAGACCGTGCTTCCACCTCGTC-3′, SEQ. ID NO 27; 5′-CCTCATCTCCTGGGTCCCTTTCA-3′, SEQ. ID NO 28).

After PCR the products were analyzed with non-denaturing polyacrylamide gel electrophoresis (PAGE) at 12 watts for 15 hours. Bands which differed between test and control were eluted from the gel, subjected to reamplification by PCR and cloned.

Example 5

Induction of cell lines with TGF&bgr;6 Influence Cellular Gene Expression.

1481-PA cells were grown overnight in DME supplemented with 10% fetal calf serum overnight at 37° C., and 5% CO2. Induction was performed by treatment with TGF-&bgr;1 at a concentration of 2 nanograms per ml. The treated cells were returned to the incubator and cultured for 12 hours. After induction, cells were washed in phosphate buffered saline and harvested and concentrated by centrifugation.

RNA was extracted from treated and untreated cells and subjected to DD-PCR. Differentially expressed bands detected by DD-PCR were cloned and differential expressions were confirmed using RNA blots (FIG. 10). Subsequent cloning and sequencing identified the bands as ABP280 or filamin.

One gene isolated showed differential expression in cells induced by TGF-&bgr; (FIG. 11, clone 29), while a control probe on the same cell line showed no difference in expression levels (FIG. 11, GAPDH).

Example 6

Metastatic Sequences Isolated.

Using the methods of Examples 1, 2, 3, 4, and 5, a plurality of metastatic sequences were isolated and sequenced. The expression of the metastatic sequences in primary cells and in metastatic cells were determined using RNA blots. The nucleic acid sequences of other isolated sequences are listed in FIG. 12. Sequence analysis and expression analysis was performed on the isolated cloned and the results of these studies are summarized in FIG. 13.

Example 7

Caveolin Immunoassay in Human Prostate Cancers.

Primary site human prostate tumors and metastases were isolated and analyzed for caveolin expression by immunoassay. The results of the assay is shown in Table 3. Metastases shows higher levels of caveolin proteins in metastases than in primary tumors. Immunohistology of tissue sections reveals both elevated levels and distinct distribution of caveolin protein in metastatic human prostate when compared to a primary human prostate tumor (FIG. 14).

TABLE 3 Patients Primary-site Metastases in lymph node 1 + ++ 2 ++ +++ 3 ++ +++ 4 ++ ++ 5 + + 6 ++ ++ 7 ++ +++ 8 + + 9 − − 10 + + 11 + + 12 ++ ++ 13 + + 14 ++ +++

Other embodiments and uses of the invention will be apparent to those skilled in the art from consideration of the specification and practice of the invention disclosed herein. The specification and examples should be considered exemplary only with the true scope and spirit of the invention indicated by the following claims.

SEQUENCE LISTING (1) GENERAL INFORMATION: (iii) NUMBER OF SEQUENCES: 175 (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 9 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: TGACAATCG 9 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: AGCTAAGGTC 10 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: TCTGCGATCC 10 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: ATACCGTTGC 10 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: TACGAAGGTG 10 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: TGGATTGGTC 10 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7: CTTTCTACCC 10 (2) INFORMATION FOR SEQ ID NO: 8: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: GGAACCAATC 10 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: TGGTAAAGGG 10 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: TCGGTCATAG 10 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CTGCTTGATG 10 (2) INFORMATION FOR SEQ ID NO: 12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: GATCAAGTCC 10 (2) INFORMATION FOR SEQ ID NO: 13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13: GATCCAGTAC 10 (2) INFORMATION FOR SEQ ID NO: 14: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14: GATCACGTAC 10 (2) INFORMATION FOR SEQ ID NO: 15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15: GATCTGACAC 10 (2) INFORMATION FOR SEQ ID NO: 16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16: TTAGCACCTC 10 (2) INFORMATION FOR SEQ ID NO: 17: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17: ACCTGCATGC 10 (2) INFORMATION FOR SEQ ID NO: 18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: GCTATACTGC 10 (2) INFORMATION FOR SEQ ID NO: 19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: AGTTGCCAGG 10 (2) INFORMATION FOR SEQ ID NO: 20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 20: AAGCCGTGTC 10 (2) INFORMATION FOR SEQ ID NO: 21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 21: TCAACGCTCA 10 (2) INFORMATION FOR SEQ ID NO: 22: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 22: TGTTCGAATC 10 (2) INFORMATION FOR SEQ ID NO: 23: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 23: CGAGTCAGAC 10 (2) INFORMATION FOR SEQ ID NO: 24: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 24: TATGAGTCCG 10 (2) INFORMATION FOR SEQ ID NO: 25: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 26 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 25: GTGTTTCATT AGTTCCCCAC CTTGAC 26 (2) INFORMATION FOR SEQ ID NO: 26: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 26: AGAGCAAGAA TAAGTCAGAA GCCG 24 (2) INFORMATION FOR SEQ ID NO: 27: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 27: ACAGACCGTG CTTCCACCTC GTC 23 (2) INFORMATION FOR SEQ ID NO: 28: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 28: CCTCATCTCC TGGGTCCCTT TCA 23 (2) INFORMATION FOR SEQ ID NO: 29: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 29: GTCCGCGCCA TGGCCATATA 20 (2) INFORMATION FOR SEQ ID NO: 30: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 30: ATGGGAGGCT GCCAGTCCTA ACCC 24 (2) INFORMATION FOR SEQ ID NO: 31: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 234 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 31: AATTTTTTTT TTCGACGGCC CAACGGAATT TTTTTTTTCG ACGGCCCAAC GGAATTTTTT 60 TTTTCGACGG CCCAACGGGA ATTCGGCTTA GCTAAGGTCA CCCAGACTTC ATGGACTTGT 120 CTATTTTCTT GCCCAAAGGG ATAGTTCCTC AGGTATTTGG GGACAGCATT CACCTCTTGC 180 AGGAGCTATG CCTGTGTGTT TGTGCTAAGT TGATACTTTC TGCGATGATC TCAC 234 (2) INFORMATION FOR SEQ ID NO: 32: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 32: TACCATCGGA GAAAGAAGAC CAAGCAAGGC TCAGGCAGCC ACCGCCTGCT TCGCACTGAG 60 CCTCCTGACT CAGACTCAGA GTCCAGCACA GACGAAGAGG AATTTGGAGA ATTGGAAATC 120 GCTCTCGTTT TGTCAAGGGA GACTATCCCG ATGCTGCAAG ATCTGCTGTC CCTCTGGCCT 180 TTGTCATCCT CGCGCCTGCG TTGTGGCCTC TGTGGGCTTG GTGTGGAGCA AATGGCTCTC 240 AAGGAGGACT GAGTCTCAAG GAAATT 266 (2) INFORMATION FOR SEQ ID NO: 33: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 33: AGCTAAGGTC AGGAGGTGTC TGAAGAATTG GCTGATGCAT GGCAGGGATG TTGTTGACCT 60 GCTTTTAGAA CAATACTTCC ATTTAATTAT AGCATATCTT ATGTGTGTAT TAAAGCAGAG 120 CCGATCTGGT GGGGCTCATT AAGTAAATGT ACTTACTGCA AAAGGTTCAA CTGGTGACCC 180 CAGTTTTCCC CAGAAGCAAT ATGATAGGAC AGAGGCGACT CCTGCAAGTT GTCTCAGACT 240 TCACACATAC ATTGTGACAT TCTCTGAGCA TGTGCACTGT ACATGATATG ACACTATCAA 300 (2) INFORMATION FOR SEQ ID NO: 34: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 34: AGCTAAGGTC CACTACCTTG TGAAGATGTA TAAACACCTG AAATGTAGAA GCGATCCGTA 60 TGTCAAGATC GAGGGGAAGG ACGCTGACGA CTGGCTGTGT GTGGACTTTG GGAGTATGGT 120 GATCCATTTG ATGCTTCCAG AAACCAGAGA AACCTATGAA TTAGAGAAAC TATGGACTCT 180 ACGTTCTTTT GATGACCTTA GCTAAGCCGA ATCAGCACAC TGGCGGCGTT ACTAGTGGAT 240 CGAGCTCGTA CAGCTGATGC ATAGCTTGAG TATCTATAGG TTACTAATAG CTGGCTATCA 300 TGTCAAGCGT TC 312 (2) INFORMATION FOR SEQ ID NO: 35: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 35: AGCTAAGGTC AAAATAAAAG CTCAAGATGA CATCAGTCCC ATTTGTCCTA AGTCCTGGTG 60 TTGTATGGAT GGTAAGCAGC AGCCAATTAT GGTGACAGGT GATAGATCCA ATTTGTTAAC 120 ATTTCTCCAT CTCTAAGCCA TCCTTAAAGA AAATCATGAA TGGAGTCACA CCATCTTCAC 180 GGTAGTCCAG GAGAGCAACC ATACCATCTG GATTCATGTT TCACCAATAA AAACTGGTAG 240 TTATTGAATT AGCAAGGATG TGCTACTCTC TGCAGCTCAG C 281 (2) INFORMATION FOR SEQ ID NO: 36: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 36: AGCTAAGGTC TCATGCAATG GAACTTAATT CTTAGAACTG TAAGAATTAC ATCAAACATA 60 AAAGCCTCCC TATTAATGTA GTCCACAAAA CTGGCAGGTA TATATGCCTT CTGAATTTGT 120 CTCCAGTGAC TTTGGTAAAT CTAACTAAAT TTTTAAAAAT TCTTAATGAA TTTATCGTCA 180 ACAACAACCA CCTCTTGGAA AATTAACCCT TGCAGTGTCT GTGTTAGACT CAGAAGTCAA 240 (2) INFORMATION FOR SEQ ID NO: 37: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 203 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 37: GAATTCGGCT TAGCTAAGGT CAGCGTGAAG TTTAAGCAGA CATGAGTCTG AAACAGTCTC 60 ATGACACATC TGATAGGATT TTTTAAGACT GCCTGGCTTA GTCTTACTGC TGTTAGTGTA 120 TATTAGGTGT TGTACACATT ATAAAGAAAA TTATGTCTCA TTATCTTGTT TAAGTCAAGG 180 AAAATAGAGA ACTTTGGTCA AAT 203 (2) INFORMATION FOR SEQ ID NO: 38: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 194 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 38: GAATTCGGCT TAGCTAAGGT CAGCGTGAAG TTTAAGCAGA CATGAGTCTG AAACAGTCTC 60 ATGACACATC TGATAGGATT TTTTAAGACT GCCTGGCTTA GTCTTACTGC TGTTAGTGTA 120 TATTAGGTGT TGTACACATT ATAAAGAAAA TTATGTCTCA TTATCTTGTT TAAGTCAAGG 180 AAAATAGAGA ACTT 194 (2) INFORMATION FOR SEQ ID NO: 39: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 230 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 39: GAATTCGGCT TAGCTAAGGT CAAAATACAC GGATTGCAAT CACTTTTCTA AACAAAAGAA 60 ACAAAGTAAC TGCTGAGGTT AGCAAAGATG AGTTCTCGTC ATACTGCCTT GTACTGTTTT 120 GTGAACTGTG TTATTAAAAA TCTGAGCTTA ACAAAATCTT TACAAGTCAC CTCATGAAAA 180 CAGCATTTGG CCAATAAGAG TTTAATTCCA CACCAGTGAG ACCTTAGCCT 230 (2) INFORMATION FOR SEQ ID NO: 40: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 242 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 40: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCC CACCATTCTC ATATATACTA CTTTCTCTTC 240 TT 242 (2) INFORMATION FOR SEQ ID NO: 41: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 41: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCC ACCATTCTCA TATATCTACG TCTCTTCTAG 240 (2) INFORMATION FOR SEQ ID NO: 42: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 154 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 42: GAATTCGGCT TTCTGCGATC CTAGAGCAGG TAAGTGAAGA AGGCCAGTAA GTTTTAAGGA 60 TGGCCTTGTT GCCTTCTATC AAGTTCTCTG GGACTTTGTA ATTTTGATTA CTACTATTGA 120 TACATGGTTA TGGTCAGAAG GCCTCTTCTC CCTT 154 (2) INFORMATION FOR SEQ ID NO: 43: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 43: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATT GGCTGGAAAG ATTACACTGC 60 CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTAC ATGAGAGTCT TAGTGCATGA 120 AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGAC CAAACCTACG CTGGTGGACG 180 GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCG GACCTCAAGT ATGAGTGCAG 240 AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2) INFORMATION FOR SEQ ID NO: 44: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 285 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 44: TGACCATCGA GTGCATCAGC CTCATCGGGC TGGCCGTCGG GAAGGAGAAA TTCATGCAGG 60 ATGCTTCAGA TGTGATGCAG CTATTGTTGA AGACACAGAC AGACTTCAAT GATATGGAAG 120 ATGACGACCC CCAGATTTCT TACATGATCT CAGCATGGGC CAGGATGTGC AAAATCTTGG 180 GAAAGAATTC CAGCAGTACC TTCCCGTGGT TATGGGGCCG CTGATGAAGA CTGCTTCAAT 240 TAAGTCCTGA GTGCCTCTAG ACACCAGGAC ATGAGATATG AGGTA 285 (2) INFORMATION FOR SEQ ID NO: 45: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 45: TGACCATCGT GTAGTTGGTG TGCTTGTTGT CGAAGATGAG GGCCTCCTGG ATGAGCTGGT 60 GCTGCTGCTC CAGCAGGTCC AGGCTGGGCT TGTAGTCCAC GATGCTGCGC TCGTACTGCT 120 TCAGGTGGCT CAGCTGGTCT TCCAGAGTCC CGTTCATCTC AATGGAGATG CGCCCGATCT 180 CCTCCATCTT AGTCTGGATC CACGGCCCCA CCATATTGGC TTGGCTGGCG AACTGTCGGC 240 GAAGGCTGCA TTGGATTGCT 260 (2) INFORMATION FOR SEQ ID NO: 46: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 283 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 46: TGACCATCGA ACACCCCAAC ACTCTCCACT ACCTGCCATT TCTTCCAGCC TTATCCACAC 60 CACCCCGTTT CTCCTGAAGA CTGATTTGCT TAGCAACTGC ACTGAGCCAA CCCTGAAGAC 120 ACATGATTAT TGGTTGGGCT CCATTAAACA ACAAGCCTAG TGCTTGGGAA GGGGGGTGGG 180 GAGGGGAAGA GACGTGAGAA GCATGTTGGC GTAGACCTTG AGGCATGGAT GAAGCATCTG 240 CCGGCCTGAC CTGGTACAGG TGGCATCTGC ACTGCAGCAA GGC 283 (2) INFORMATION FOR SEQ ID NO: 47: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 277 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 47: TGACCATCGA AGTGCAAAGG AAATGACTTG ATTTCATGAA GTATCTCCAG AAGTAACGCT 60 TTGTTTTCTG CATCCTGAAC TTTATTCCCA GTGAAGAGCT GAAAATCTGG ACGCTCAAAA 120 AATGGAAGCA CTTTGGAGAG AGCCCTTAAC TCTATCAGGT ACAGGAAGTA CAAGTTCCTC 180 AGCCTTCGTG GGCCTTCTCC TTCAGTCAGA ATCCATCAAA GGTGCTGGAA CTCTGTGACA 240 TTGTGACCCA TTCTTTCAGC CAGTATCTGT AAGATAC 277 (2) INFORMATION FOR SEQ ID NO: 48: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 48: GGGAACGAAT GATCTGGAAC TGTGGCTTGT AGACAACCCA AATATCTTAG GTAGGTAAGA 60 AATTCCAGCA TCACACTATA TAGGAAATAC TGTGCGAAAC TGACAGTTAA CTGTGCACAA 120 AGTTCAATGG CTTCAAAATA ATGTATAAAG GATAAGAAGA AACCAGTTTA CCATTTTGGT 180 ATTATTTTGG TTGCTTTGTA TAACTTCAAT AATTT 215 (2) INFORMATION FOR SEQ ID NO: 49: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 215 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 49: GGGAACGAAT GATCTGGAAC TGTGGCTTGT AGACAACCCA AATATCTTAG GTAGGTAAGA 60 AATTCCAGCA TCACACTATA TAGGAAATAC TGTGCGAAAC TGACAGTTAA CTGTGCACAA 120 AGTTCAATGG CTTCAAAATA ATGTATAAAG GATAAGAAGA AACCAGTTTA CCATTTTGGT 180 ATTATTTTGG TTGCTTTGTA TAACTTCAAT AATTT 215 (2) INFORMATION FOR SEQ ID NO: 50: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 10 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 50: GACGTAAGCC 10 (2) INFORMATION FOR SEQ ID NO: 51: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 189 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 51: CCACAAAGCA AGCTTCTGTC TGGAGTACAG CTCCTGTGAC TATGGGTACC ACAGGGCCTT 60 TGCGTGCACT GCACACACAC AGGGATTGAG TCCTGGATGT TATGACACCT ATGCGGCAGA 120 CATAGACTGC CAGTGGATTG ATATTACAGA TGTACAACCT GGAAACTACA TTCTAAAGGT 180 CAGTGTAAA 189 (2) INFORMATION FOR SEQ ID NO: 52: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 227 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 52: CTATCAATGA AGGGGGAGAT CACTGGGTAA GTTCGAATGC CCTCAGGCAA GGTGGCCCAG 60 CCTTCCATTA CTGAATTCAA AGATGGCACT GTTACTGTAC GTTACTCACC CAGTGAAGCT 120 GGCCTGCATG AAATGGACAT TCGCTATGAC AATATGCATA TCCCAGGAAG CCCTCTGCAG 180 TTCTATGTTG ATTATGTCAA CTGTGGCCAC ATCACTGCTT ATGGTCC 227 (2) INFORMATION FOR SEQ ID NO: 53: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 373 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 53: TTAGCACCTC GACCACGAAA TGAGGAAGAT GCAACAGACG TGGTGGGCCT GGCTCAGGCT 60 GTAAACGCTC GGTCCCCACC TTCAGTAAAA CAGAACAGCT TGGATGAAGA CCTTATTCGG 120 AAGCTAGCTT ATGTTGCTGC TGGGGACCTG GCACCCATAA ATGCTTTCAT TGGGGGCCTT 180 GCTGCCCAGG AAGTCATGAA GGCCTGCTCT GGAAAGTTTA TGCCCATCAT GCAGTGGTTG 240 TACTTTGATG CTCTTGAATG TCTCCCAGAA CGGACAAAGA GGCTCTGACA GAGGAGAGTG 300 CCTCCCACGT CAGAACCGTT ACGATGGGCA GGTAGCTGTA TTGGTCAGAC TTCAGGAGAA 360 GCTGAGAAGC AAA 373 (2) INFORMATION FOR SEQ ID NO: 54: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 257 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 54: TTAGCACCTC CAATGGCTGG GTACCAGCCA GCCGCAATGT CCGCTCCACA AATTTGGAGT 60 CTGTGAGGTA CTGATTAACA TTTTCTGCTG GCTGCTTGAA AAGGCCTTCA AATTCATCCC 120 GGGCCCACTG AAGAGTGTGT TCGATGGCAT TGGGAAAGTT TTTCAGGGTA CAAATGGGGA 180 TGGATTTCTC TGGTGGATCC TGGCTAGACG TGATGGATTC TGTCAGGAAG GGGATTACCA 240 CCTGCACGTT GCCCTTT 257 (2) INFORMATION FOR SEQ ID NO: 55: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 298 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 55: TTAGCACCTC ACACTCACAT GCCCTTCTAC ATAGAGACTG GTTAAACAGC CCTCCCTCCC 60 TTGTCCCGAC TTGACTTCCA GGCCCCTCTG CTTTCCTCTC ACAACCACAC CAGGTCTGAT 120 GGAGTCCAGT GCCTGCAGTG ACCCAACATA GACTGCACTT TCACCTACCT ACTGGATGGT 180 CCTGCAGCCC AGACGGCTGC TCTTCTTTCT CATGGAGTTT CTCTCCTGCC TGAGATATGC 240 TATCTGGTCT GCCCCTGTGT AGCTCCCATG GGATCCCTTA AAATCGATCC TTTTTTAA 298 (2) INFORMATION FOR SEQ ID NO: 56: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 56: TTAGCACCTC GTGAGGAGAC TGTTGTCCAC AGGCCAGCTA GTGGTACCCT ACTGAGAAGT 60 TGGGTTTTGG TTTTGTTTCC CTTGAAGGGT CGCTGTTAGA GGATGGAAGT AACTTCTAAT 120 TCTTGATCTG TTTGTTGGTC TTGTTTTCAG TACTTTTTGC CAGTTGTATA CACTTGGAGA 180 GGGAATTTGT ATGCCTGTAA TCTTGTTCTT GAGGTCAGAA ATTCAAAACA TTGGGAGCTT 240 TTGTTGTAAA GGTTAAACTG TGAATCCATA TAGCAAATGC AGATCCTTTT ACAGTGTAAA 300 CCACATTTCC TGCCTCAGCC TAAAGCACTG GTCATTT 337 (2) INFORMATION FOR SEQ ID NO: 57: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 333 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 57: ACCTGCATGC CTAAAGGAGT AGGCTTAGGG GTGGGGAGAG AGAAGGCATA GGCTTTTCTA 60 GTTATACAAA GCTGTGTAAG GCAAGGTTCC TTTCTACTAA ATGGTCAGCT GTCACTACAT 120 TTATACTTTT GTATGTCATA AACCCTTTCT TTCATTCCTC CCTGGGTAAC CAGGACAATC 180 GGAGGGCAGT GTGTTACTGG GATTAGAGGA CTAGCAATAC TGGGTAACCC GCCTAAGCTG 240 GAAGGTGACG TAATACGTTT CTTTAAAGAT TCAGTCAGTC AAGCAGTTTA GCAATATCAA 300 AATGTCTGGC TGTTTGGTCC AGTGTACACT GTT 333 (2) INFORMATION FOR SEQ ID NO: 58: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 58: GCTATCTGCG AAACTACAGA AAGGAAGACA GCTTGGCCCA GCGCGGTGAA GTTCAGAATT 60 CACTAGGTAG TTGTTGTTGG TTGACTTGGA GGTAGCTGGG TAATCAACAG CTTTCACTTT 120 AGATTCAATG TGAACCGCAG AGTTACTCAT GACCAAGAGT CTGGCAAACT CATTAATGCT 180 GTTTAATACT TGTTTGATAT TTTTTCACCT TTTGAGCCCT TTTCCCAAAG AATTCAATAT 240 CAGTTTAGTA GCAACAGTAC AGTTGCCATT TAAATTGGTT TAGTTGCAGT ATAGCA 296 (2) INFORMATION FOR SEQ ID NO: 59: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 296 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 59: GCTATCTGCG AAACTACAGA AAGGAAGACA GCTTGGCCCA GCGCGGTGAA GTTCAGAATT 60 CACTAGGTAG TTGTTGTTGG TTGACTTGGA GGTAGCTGGG TAATCAACAG CTTTCACTTT 120 AGATTCAATG TGAACCGCAG AGTTACTCAT GACCAAGAGT CTGGCAAACT CATTAATGCT 180 GTTTAATACT TGTTTGATAT TTTTTCACCT TTTGAGCCCT TTTCCCAAAG AATTCAATAT 240 CAGTTTAGTA GCAACAGTAC AGTTGCCATT TAAATTGGTT TAGTTGCAGT ATAGCA 296 (2) INFORMATION FOR SEQ ID NO: 60: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 273 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 60: GCTATACTGC AACTAAACCA ATTTAAATGG CAACTGTACT GTTGCTACTA AACTGATATT 60 GAATTCTTTG GGAAAAGGGC TCAAAAGGTG AAAAAATATC AAACAAGTAT TAAACAGCAT 120 TAATGAGTTT GCCAGACTCT TGGTCATGAG TAACTCTGCG GTTCACATTG AATCTAAAGT 180 GAAAGCTGTT GATTACCCAG CTACCTCCAA GTCAACCAAC AACAACTACC TAGTGAATTC 240 TGAACTTCAC CGCGCTGGGC CAAGCTGTCT TCC 273 (2) INFORMATION FOR SEQ ID NO: 61: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 322 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 61: GCTATACTGC CCACCACATT GCCACACTCG GAATGACATT TCTATATTTT CACCTCCCCA 60 GATTTCCATT TCTTCATCGT AACTTCCAAT GTGCTCAAAA TATTTTTTAG ATATAGAAAA 120 AAGGCCTCCT GCAAAGGTGG GGGTCTTAAT TGGGTAGGTT TCATCTTTCC TTCTTTGCTT 180 CTCATGATCA GGAAGTGACT CCCAGCCAAA GGAAAGGCTC CAGTCAAAAT TTCCACGGTT 240 ATGGTTGCTT CCGTACGGAG AAGGCTTGTT GAATTCAAAT GTGTTTAGAT CTATGGATGC 300 GATGTCTGGA CTCACCACGG CA 322 (2) INFORMATION FOR SEQ ID NO: 62: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 62: GCTATACTGC TGAAGGAGAT CATTTTGGTG GATGATGCTA GTGTAGACGA CTACCTGCAT 60 GAAAAGCTGG AGGAATACAT AAAACAGTTT TCTATTGTGA AAATAGTCAG GCAGCAAGAA 120 AGGAAAGGCC TGATCACCGC GCGGTTGCTA GGGGCAGCTG TAGCAACTGC CGAGACGCTC 180 ACGTTCTTAG ATGCTCACTG TGAGTGCTTC TATGGCTGGC TGGAACCTCT GCTGGCCAGG 240 ATAGCTGAGA ACTACACTGC CG 262 (2) INFORMATION FOR SEQ ID NO: 63: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 63: AGTTGCCAGG GGGCAGCTCA CGGCGCAGCT CATCCTCTGT GATGTAATTC TTATCTCCAG 60 CCAGGATCTT GAAGGAAGCC ATGACCTGAT CTGCAGTATC AGTATCTGCC GTCTCTCGGG 120 ACATAAAGTC GATGAAGGCC TGGAACGTCA CTACCCCCAA GCGGTTGGGG TCTACAATGC 180 TCATGATTCG GGCAAACTCT GCCTCTCCCA TGTTGTAACC CATGGAGATA AGGCAGGCGC 240 GGAAATCGTC TGTGTCCATC ATGCCCGTCT TCTTCCGGTC AAAGTGGTTG AAAGA 295 (2) INFORMATION FOR SEQ ID NO: 64: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 64: AAGCCGTGTC GCTGAACTGG GAGGACACAC TGCTCACCCT AGAAGGCTCT GGCTGACCCT 60 CCGCCCGGTT AAACAGGGAC TTTGTGGCCA TGTGCTGGCG ACACAGGTCC TGGTACTCAA 120 AAGTAGTGTC ACCATGGGCC CCCTCCGGCC CCAGCGCTGC CAGGCGTCCT TATCCCGCTG 180 TCTCGAATGA TGGCGCATAC CAAGGCCACT GAAAGCCACT AGCAGCCCAG CGACGCCTGC 240 CAGGGCCACT AGAGTAAGCA GCACTGAGCG CATGGGAGAT ATGCCAT 287 (2) INFORMATION FOR SEQ ID NO: 65: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 332 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 65: AAGCCGTGTC TGGACGTCCG TGTGTCCGGC TCTTGCTCAC GCAGTCATGG CCTCCGGAAC 60 GCGCAAATCG GAAAGTCGGC TCCTGACTTC ACGGCCACAG CGGTGGTGGA TGGTGCCTTC 120 AAGGAAATCA AGCTTTCGGA CTACAGAGGG AAGTACGTTG TCCTCTTTTT CTACCCACTG 180 GACTTCACTT TTGTTTGCCC CACGGAGATC ATCGCTTTTA GCGACCATGC TGAGGACTTC 240 CGAAAGCTAG GCTGCGAGGT GCTGGGAGTG TCTGTGGACT CTCAGTTCAC CCACCTGGCG 300 TGGATCAATA CCCCACGGAA AGAGGGAGGC TT 332 (2) INFORMATION FOR SEQ ID NO: 66: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 331 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 66: AAGCCGTGTC GGAGGGCACC AAGGCTGTCA CCAAGTACAC CAGCTCCAAG TGAGTGCTCA 60 AGACTCAGCT CTTAACCCAA AGGCTCTTTT CAGAGCCACT CAAGACTTCA AAATTGGAGC 120 TTTAATGCTG ACTTAGTGAC TACCGGGAAA ATAACTGACT TCATCTGCAG GATTGTGTAC 180 AAACACTTAT GGTTTAGTAA ATCGAAAAGA TAGACATTGC CCATCAGTTC TGTCTGGTCC 240 ACTTAAATAT GCTTTTTTCT TAGAAGTTCT AAGAACCCTG TCAATAACCT ATCTAGGTCC 300 AGTCCTTGAG TTCAAAGGCC AAATACCAAT G 331 (2) INFORMATION FOR SEQ ID NO: 67: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 359 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 67: CAACGCTCAG GATGTAAGCT GTTTCCAGCA CCTGGTTCAA GCGAATGTAA GAAATAAGAA 60 GGTGTTGAAA GATGCCGTGA ATAACATTAC AGCAAAGGGG ATCACAGATT ACAAGAAAGG 120 CTTTAGCTTT GCCTTCGAAC AGCTACTTAA TTATAATGTT TCCAGAGCTA ATTGCAATAA 180 GATTATCATG TTATTCACGG ATGGAGGAGA AGAGAGAGCC CAGGAGATAT TTGCCAAATA 240 CAATAAAGAC AAAAAAGTCC GTGTGTTTAC ATTTTCCGTC GGTCAACATA ATTATGACAG 300 AGGACCTATT CAGTGGATGG CTTGTGAAAT AAAGGTTACT ATTATGAGAT TCCTCCATT 359 (2) INFORMATION FOR SEQ ID NO: 68: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 68: TCAACGCTCA TCACACCAAG AATCAACTGG TTCTTCAAGT TTGTCTTATT TTCAGATTGG 60 CCAGTGACGT TGAAGACTGG TAGAGTTCCA GTAATGACAA GTCCCAGTTC CAGGGCATCC 120 AAATACACAT TTGTCCATTG AACTTGCTTC GCTTTGTCAC CAGCTAAAAC CATTGGTCTT 180 CCCAGAACAT CTAGATATTC CTGAGTATTG ATTCTTATTG CACCAATGGA GGGAATCTCA 240 TAATAGTAAC CTTTATTTTC ACAAGCCATC CACTGAATAG GTCTCTGTCA TAATTATGTT 300 GACCGACGGA AATGTAA 317 (2) INFORMATION FOR SEQ ID NO: 69: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 69: TAACGCTCAG GAGAAGAATA GGAATGCAGA GAACTCTGCC ACAGCCCCCA CGCTCCCGGG 60 CAGCACCTCA GCCACCACCG CAACCACCAC CCCTGCTGTA GATGAAAGCA AGCCTTGGAA 120 CCAGTATCGC TTGCCTAAGA CTCTTATACC TGACTCCTAC CGGGTGATCT TGAGACCCTA 180 CCTCACCCCC AACAATCAGG GCCTGTACAT CTTCCAAGGC AACAGTACTG TTCGCTTTAC 240 CTGCAACCAG ACCACGGATG TCATTATCAT CCACAGCAAA AAGCTCAACT ACACCCTCAA 300 AGGAAACCAC AGGGTGG 317 (2) INFORMATION FOR SEQ ID NO: 70: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 287 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 70: CGAGTCAGAC GGCTTCAGCA TCGAGACCTG TAAGATCATG GTGGACATGC TGGATGAAGA 60 TGGGAGTGGC AAGCTTGGCC TGAAGGAGTT CTACATCCTC TGGACGAAGA TTCAGAAATA 120 CCAAAAAATC TACCGGGAAA TCGATGTGGA CAGGTCTGGA ACTATGAATT CCTACGAGAT 180 GCGGAAAGCA CTGGAAGAAG CAGGTTTCAA GCTGCCCTGT CAACTCCATC AAGTCATCGT 240 TGCCCGGTTT GCAGACGACG AGCTAATCAT CGACTTTGAC AATTTTG 287 (2) INFORMATION FOR SEQ ID NO: 71: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 71: CGAGTCAGAC AACCTGTTCA AGTGGGGTGG GGACCATCCA CGGAGCAGCC GGCACCGTAT 60 ATGAAGACCT GAGGTACAAA CTCTCCCTAG AGTTCCCCAG CGGCTACCCT TACAACGCAC 120 CCACAGTGAA GTTCCTCACA CCCTGCTACC ACCCCAACGT GGACACCCAG GGCAACATCT 180 GCCTGGACAT CCTCAAGGAT AAGTGGTCTG CACTATATGA TGTCAGGACT ATCTTGCTCT 240 CTATCCAGAG CCTGCTAGGA GAACCCAACA TCGATAGCCT TTGAACACAC ACGCTGCGGA 300 ACTCTGGAAA A 311 (2) INFORMATION FOR SEQ ID NO: 72: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 352 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 72: TATGAGTCCG GAGCGACGGC TACGAGTGTG AACTGTTCCA GCCCCGAGCG ACACACCAGA 60 AGTTATGACT ACATGGAAGG AGGGGATATA AGGGTGAGAA GACTGTTCTG TCGCACCCAG 120 TGGTACCTGA GGATTGACAA ACGAGGCAAA GTGAAAGGGA CCCAGGAGAT GAAGAACAGC 180 TACAACATCA TGGAAATCAG GACCGTGGCA GTTGGAATTG TGGCAATCAA AGGGGTGGAA 240 AGTGAATACT ATCTTGCCAT GAACAAGGAA GGGAAACTCT ATGCAAAGAA AGAATGCAAT 300 GAGGATTGCA ACTTCAAAGA ACTGATTCTG GAAAACCATT ATAACACCTA TG 352 (2) INFORMATION FOR SEQ ID NO: 73: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 317 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 73: TATGAGTCCG AGGAGGAGCA CAATGCTGGG AGTGTGGAAA GCCAGGTTGT CCCCAGCACA 60 CACCGAGTGA CCGATTCCAA GTTCCATCCA CTCCATGCCA AGATGGATGT CATCAAAAAA 120 GGCCACGCCA GGGACAGCCA GCGCTACAAA GTTGACTATG AGTCTCAAAG CACAGACACC 180 CAGAACTTCT CCTCCGAGTC TAAGCGGGAG ACAGAATACG GTCCCTGCCG CAGAGAAATG 240 GAGGACACAC TGAATCATCT GAAGTTCCTC AATGTGCTGA GTCCAGAGTC TCACATCCAA 300 ACTGTGACAA GAAGGGG 317 (2) INFORMATION FOR SEQ ID NO: 74: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 74: TCGCCCGGGA CTTCATGCGA TTGAGAAGAT TGTCTACCAA ATATAGAACA GAAAAGATTT 60 ATCCCACAGC CACTGGAGAA AAAGAAGAAA ATGTTAAAAA GAACAGATAT AAGGACATAC 120 TGCCATTTGA TCACAGCCGA GTTAAGTTGA CTTTGAAGAC TCCATCCCAA GATTCAGATT 180 ATATCAATGC AAATTTTATT AAGGGTGTGT ATGGGCCAAA AGCATATGTG GCAACCCAAG 240 GGCCTTT 247 (2) INFORMATION FOR SEQ ID NO: 75: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 75: TGTGGAAAGC CAGGTTGTCC CCAGCACACA CCGAGTGACC GATTCCAAGT TCCATCCACT 60 CCATGCCAAG ATGGATGTCA TCAAAAAAGG CCACGCCAGG GACAGCCAGC GCTACAAAGT 120 TGACTATGAG TCTCAAAGCA CAGACACCCA GAACTTCTCC TCCGAGTCTA AGCGGGAGAC 180 AGAATACGGT CCCTGCCGCA GAGAAATGGA GGACACACTG AATCATCTGA AGTTCCTCAA 240 TGTGCTGAGT CCAGAG 256 (2) INFORMATION FOR SEQ ID NO: 76: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 383 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 76: TGACCATCGA AGTGCAAAGG AAATGACTTG ATTTCATGAA GTATCTCCAG AAGTAACGCT 60 TTGTTTTCTG CATCCTGAAC TTTATTCCCA GTGAAGAGCT GAAAATCTGG ACGCTCAAAA 120 AATGGAAGCA CTTTGGAGAG AGCCCTTAAC TCTATCAGGT ACAGGAAGTA CAAGTTCCTC 180 AGCCTTCGTG GGCCTTCTCC TTCAGTCAGA ATCCCATCAA AGCGCTGCTG GAACTCTGTG 240 ACATTGTGAC CCCATTTCTT TTCCAGCCAA GTATCTTGTA AAAGATACCT TGCACTCAAA 300 TGCACATTAA TGCTTGCGTG CAGGCCAGAT ATAAGTCTGT AGAATCGCTC TTTCTACACA 360 GAGGCCTTCT AGCCAGTTGT AAA 383 (2) INFORMATION FOR SEQ ID NO: 77: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 400 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 77: CTGCTTGATG CTAAGCCCGG CAGCCTGTGT TTCATCTACA GGATGCACAA CATAAAAGAA 60 AAGATCTGAT TCCCGCAGGT TCTCTTCTGA CCTACACACA CACACACTAA AATAACATTT 120 AAAAATATGT GCCAAATTAT ATTTGTTCGG GTGCCACCTT CCACCAGCTT ACCACTACGG 180 TAGAACTGTC AAATTCATCT CCCTGAATTT GTCTTAAAGG GGTGTCCATG CACAGGCCCA 240 AGAGTCACCT CCAATGAAAT AAATGTAATA CTGAAGTATG CCATGATGTT TGTTGTTTTC 300 TTTCATCGTA AGCCTGTAAG CAGGAAAAAT AGTAATAGAT AGAATAGAGA CTTACCAGTG 360 GTCGATGGCC TGGTCAGTCT GTGCGGTGAC TAGGACCAGG 400 (2) INFORMATION FOR SEQ ID NO: 78: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 343 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 78: ACCTGCATGC CGAGTGTGAC GCCTTTGAGG AGAAGATCCA GGCTGCCGGA GGGATCGAAC 60 TCTTTGTCGG AGGCATTGGC CCCGATGGAC ACATTGCCTT CAATGAGCCA GGCTCCAGCC 120 TGGTGTCCAG GACCCGTGTG AAGACTCTGG TTATGGACAC CATCCTGGCC AACGCTAGGT 180 TCTTTGATGG TGATCTTGCC AAGGTGCCCA CCATGGCCCT GACAGTGGGT GTCGGCACTG 240 TCATGGATGC TAAAGAGGTG ATGATCCTCA TCACAGGCGC TCACAAGGCC TTTGCTCTGT 300 ACAAAGCCAT CGATGGAGGC GTGAACCACA TGTGGACGGT GTG 343 (2) INFORMATION FOR SEQ ID NO: 79: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 79: GCTATACTGC AATGTTAGGG GAATGAACGC GTTTTCCTAC TGCACTGGGG ACTTTTAGAT 60 AGGTTAATGA AAGGCCTTTT ATTCTGTTAC TGGACACGAA AACTTTGTCT AATTTCTTAT 120 ACTCTATTGT ACGTTTACAG TCGCAGCACT AAAATGGAAG ACATCAAACA TTTTTAACAG 180 AAAAAAAAAA AGATGTAAAA ACTAACTAAG GACTATTTAT TGATAATGTT TTGCTACTCC 240 TGTCAGACAA TGGCTATAAA CTGAATTAGG CAGTCTTAAA AAAAAAAAAA GAAAAAAAAG 300 AAAAAAGAAA AAAAGAAAAG AAAAGAAAAA AAACTGG 337 (2) INFORMATION FOR SEQ ID NO: 80: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 371 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 80: AGCTAAGGTC GGGTACTCTG ATACTTCAGA GTTTAAAATC ATCAGCCCTT GTAGATCTAT 60 TCCTAAATCT TATGAAAATG CTCAGATGTT TACACAGCTG TGAAACAGGG TCAGTTCAGA 120 TCGCTGATGG CTTGAGAATG TGTTTCTTGT TGACATCAGG AACTGGAAAT GTTTACTTCC 180 CGTCATTTAT GAGTCATCAA GTATCTCGGC TCTTTTAAGA GCGCAAGATA AAACAAGCTT 240 AAACCAGGTG ATAAGAGCAG AGTCCACTTG AGTCTGAGCT CACCCGAGAA CTTGCTATCG 300 AGGACATTTG GAATGGGAGT GTGCAGGCTT CCTTCAGTTA CTGAATGAGT CCATCTGCTA 360 GTCACCTTGA C 371 (2) INFORMATION FOR SEQ ID NO: 81: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 319 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 81: AGCTAAGGTC CAGGGGGCAA AGCGGTGACG TGTGCACATC GATATGAGAA ACGGCAGCAC 60 GTCAACACGA AGCAGGAGTC GCGGGATATC TTTGGAAGAT GTTATGTCCT AAGTCAGAAT 120 CTCAGAATTG AAGATGATAT GGACGGAGGA GACTGGAGTT TCTGCGATGG CCGGTTGAGA 180 GGCCATGAAA AGTTTGGCTC CTGTCAGCAA GGAGTAGCGG CTACTTTCAC TAAGGACTTT 240 CATTACATTG TTTTTGGAGC CCCAGGGACT TACAACTGGA AAGGGATCGT CGTGTAGAAC 300 AAAAGAATAA CACTTTTTT 319 (2) INFORMATION FOR SEQ ID NO: 82: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 368 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 82: AAGCCGTGTC TGTGCTCAAG GAAGAAACCC ACTGGACCAA CTTCTGTCAG AAAGGAAAAC 60 CTTGTTCAAA GTTTCAGGAC CCTGTTCTTT GCTTATTTGC ACATGGTCAC CTTGGTCTGA 120 GCTAGCCACC ATTGTCACCC ACAGCTGCAA AGAAAGCAGA CCTTAGGAAA CACTGTCACG 180 GCTGAGTGTG ACTGCCTTGT TCATCCCCTG GACTGGTACT GTGTTGCCTG CAGTACCATT 240 GGGATCCCAT AGCAAGAGAG GGAGAGGGAG ATGTTAGTTA GCCTTTGCTA CGAACCAAGC 300 TGTCCCAAGT CTCAACAGCT AAACAGGTAT TCATTTACCA TGATTCTATG GTTAGCTAAG 360 CTCTTGAG 368 (2) INFORMATION FOR SEQ ID NO: 83: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 340 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 83: CTTTCTACCC TGGAGGATGT GCTTGAGGCA CACTGCTCCT GTGCTCTCCA CTTGAGGCAT 60 AAGCCCAGTC AGTTGTGCAT AGATGATTAA CCTCTGACCC CTAAAGATGG TAAGTTGCTC 120 TGGAGAAAGC ATTTTAACAG ACAAACCAGG AGGCAAATCC CAACTTAGAG AGATGTTATC 180 CACTGCACAC TGTAGAGCAA ACTTGAGAGA CCCAAGAGCC TTGGTCTGCA TCCTGTCCTT 240 GCCTGTGATA AACACTCGAG TACCCCCTGA TACCGGGCGA TATTTTTGAT TAACTGGTCG 300 AGGCTCCTTG TCCAATTCCA AAAGAGAACA TCTGTGTTTC 340 (2) INFORMATION FOR SEQ ID NO: 84: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 252 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 84: TGGTAAAGGG CATCTGTAAA TACACTCTAT GAGGAAATTA AAACTTGAAC ATGGCAGTCT 60 GACATTGCAA AACAAAACAA AACAAAACTG ACCCTCCAAT AGCAGCGAAA ACAACGTGAA 120 AGATACAAAG CAATGAGAAT CTGGTTCTGA ACGCCTGGGA TCCTGGGAGT CATCGGTAGC 180 AGCGCCATGA GAGGAGCCGT GGCCTGTCCC ATGTGGTCCC ACCTTCACCT CTTCCCTCAC 240 ATCCCTCTTA AG 252 (2) INFORMATION FOR SEQ ID NO: 85: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 348 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 85: TGGTAAAGGG GGCAAGGGCA AAGGCACGGG AGACAGAGGC CACTGCATCT GTACCCACAT 60 CAGACATGTT TGTCCATTTT CTCTCATTTG GCCTTAGACC ATTGGCAAGA GTAAATGCTC 120 TTAGTCCCGT TATCTAGAAA TTTCTTCCTT TGGGGAGAAC CACTTATAGA CAATATCAGC 180 TCTCTACAAA TAACACGAAA GGTCGTAACA CAGCAAGTGA CCAGAAAGTG CCCGTCCTTG 240 CGGCTCTGAT CCACGTGGCT CTCCGTAGAC AAATTGTTTT TTCTTGTAGG GATATCTGTT 300 TTGCTTCTGA ACTTTCTTAC AAGTGTTTGG GACTCTTCGG GTGGCGTT 348 (2) INFORMATION FOR SEQ ID NO: 86: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 351 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 86: TGGTAAAGGG TCAAGTGTTC GATCAGAGTG GAGCTCCATT ACCGAATGTA ATCGTGGAAG 60 TCCAAGACAG AAAGCATATC TGCCCGTTTA GAACCAACAA GCTTGGAGAA TACTATCTGC 120 TTCTGCTGCC CGGGTCCTAC GTGATCAATG TTACAGTCCC TGGACACGAC TCCTACCTCA 180 CGAAGCTTAC TATTCCAGGG AAATCCCAGC CCTTCAGTGC TCTTAAAAAG GATTTTCACC 240 TCCCGCTGCG ATGGCAGCCG GATTCCATCT CCGTATCCAA TCCTTCGTGC CGATGATTCC 300 GCTGTACAAA TTCATGCCAA GCCACTCGGC TGCCACAAAG CCTAGTCTGG G 351 (2) INFORMATION FOR SEQ ID NO: 87: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 242 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 87: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCC CACCATTCTC ATATATACTA CTTTCTCTTC 240 TT 242 (2) INFORMATION FOR SEQ ID NO: 88: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 88: GAATTCGGCT TTCTGCGATC CACTCTTTGA AGCTATTGGC AAGATATTCA GCAACATCCG 60 CATCAGCACG CAGAAAGAGA TATGAGGGAC ATTTCAAGGA TGAAAGGTTT TTTTCCCCCC 120 TTACTATTTC CTTGGTGCCA ATTCCAAGTT GCTCTCGCAG CAGCAAATTT ATGAATGGTT 180 TGTCTTGATC AAGAACAAAG AATTCATTCC ACCATTCTCA TATATCTACG TCTCTTCTAG 240 (2) INFORMATION FOR SEQ ID NO: 89: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 687 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 89: ACGAGGGGAA ACCTCCTCAG AGCCTGCAGC CAGCCACGCG CCAGCATGTC TGGGGGCAAA 60 TACGTAGACT CCGAGGGACA TCTCTACACT GTTCCCATCC GGGAACAGGG CAACATCTAC 120 AAGCCCAACA ACAAGGCCAT GGCAGACGAG GTGACTGAGA AGCAAGTGTA TGACGCGCAC 180 ACCAAGGAGA TTGACCTGGT CAACCGCGAC CCCAAGCATC TCAACGACGA CGTGGTCAAG 240 ATTGACTTTG AAGATGTGAT TGCAGAACCA GAAGGGACAC ACAGTTTCGA CGGCATCTGG 300 AAGGCCAGCT TCACCACCTT CACTGTGACA AAATATTGGT TTTACCGCTT GTTGTCTACG 360 ATCTTCGGCA TCCCAATGGC ACTCATCTGG GGCATTTACT TTGCCATTCT CTCCTTCCTG 420 CACATCTGGG CGGTTGTACC GTGCATCAAG AGCTTCCTGA TTGAGATTCA GTGCATCAGC 480 CGCGTCTACT CCATCTACGT CCATACCTTC TGCGATCCAC TCTTTGAAGC TATTGGCAAG 540 ATATTCAGCA ACATCCGCAT CAGCACGCAG AAAGAGATAT GAGGGACATT TCAAGGATGA 600 AAGGTTTTTT TCCCCCCTTA CTATTTCCTT GGTGCCAATT CCAAGTTGCT CTCGCAGCAG 660 CAAATTTATG AATGGTTTGT CTTGATC 687 (2) INFORMATION FOR SEQ ID NO: 90: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 560 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 90: Met Glu Cys Leu Tyr Tyr Phe Leu Gly Phe Leu Leu Leu Ala Ala Arg 1 5 10 15 Leu Pro Leu Asp Ala Ala Lys Arg Phe His Asp Val Leu Gly Asn Glu 20 25 30 Arg Pro Ser Ala Tyr Met Arg Glu His Asn Gln Leu Asn Gly Trp Ser 35 40 45 Ser Asp Glu Asn Asp Trp Asn Glu Lys Leu Tyr Pro Val Trp Lys Arg 50 55 60 Gly Asp Met Arg Trp Lys Asn Ser Trp Lys Gly Gly Arg Val Gln Ala 65 70 75 80 Val Leu Thr Ser Asp Ser Pro Ala Leu Val Gly Ser Asn Ile Thr Phe 85 90 95 Ala Val Asn Leu Ile Phe Pro Arg Cys Gln Lys Glu Asp Ala Asn Gly 100 105 110 Asn Ile Val Tyr Glu Lys Asn Cys Arg Asn Glu Ala Gly Leu Ser Ala 115 120 125 Asp Pro Tyr Val Tyr Asn Trp Thr Ala Trp Ser Glu Asp Ser Asp Gly 130 135 140 Glu Asn Gly Thr Gly Gln Ser His His Asn Val Phe Pro Asp Gly Lys 145 150 155 160 Pro Phe Pro His His Pro Gly Trp Arg Arg Trp Asn Phe Ile Tyr Val 165 170 175 Phe His Thr Leu Gly Gln Tyr Phe Gln Lys Leu Gly Arg Cys Ser Val 180 185 190 Arg Val Ser Val Asn Thr Ala Asn Val Thr Leu Gly Pro Gln Leu Met 195 200 205 Glu Val Thr Val Tyr Arg Arg His Gly Arg Ala Tyr Val Pro Ile Ala 210 215 220 Gln Val Lys Asp Val Tyr Val Val Thr Asp Gln Ile Pro Val Phe Val 225 230 235 240 Thr Met Phe Gln Lys Asn Asp Arg Asn Ser Ser Asp Glu Thr Phe Leu 245 250 255 Lys Asp Leu Pro Ile Met Phe Asp Val Leu Ile His Asp Pro Ser His 260 265 270 Phe Leu Asn Tyr Ser Thr Ile Asn Tyr Lys Trp Ser Phe Gly Asp Asn 275 280 285 Thr Gly Leu Phe Val Ser Thr Asn His Thr Val Asn His Thr Tyr Val 290 295 300 Leu Asn Gly Thr Phe Ser Leu Asn Leu Thr Val Lys Ala Ala Ala Pro 305 310 315 320 Gly Pro Cys Pro Pro Pro Pro Pro Pro Pro Arg Pro Ser Lys Pro Thr 325 330 335 Pro Ser Leu Gly Pro Ala Gly Asp Asn Pro Leu Glu Leu Ser Arg Ile 340 345 350 Pro Asp Glu Asn Cys Gln Ile Asn Arg Tyr Gly His Phe Gln Ala Thr 355 360 365 Ile Thr Ile Val Glu Gly Ile Leu Glu Val Asn Ile Ile Gln Met Thr 370 375 380 Asp Val Leu Met Pro Val Pro Trp Pro Glu Ser Ser Leu Ile Asp Phe 385 390 395 400 Val Val Thr Cys Gln Gly Ser Ile Pro Thr Glu Val Cys Thr Ile Ile 405 410 415 Ser Asp Pro Thr Cys Glu Ile Thr Gln Asn Thr Val Cys Ser Pro Val 420 425 430 Asp Val Asp Glu Met Cys Leu Leu Thr Val Arg Arg Thr Phe Asn Gly 435 440 445 Ser Gly Thr Tyr Cys Val Asn Leu Thr Leu Gly Asp Asp Thr Ser Leu 450 455 460 Ala Leu Thr Ser Thr Leu Ile Ser Val Pro Asp Arg Asp Pro Ala Ser 465 470 475 480 Pro Leu Arg Met Ala Asn Ser Ala Leu Ile Ser Val Gly Cys Leu Ala 485 490 495 Ile Phe Val Thr Val Ile Ser Leu Leu Val Tyr Lys Lys His Lys Glu 500 505 510 Tyr Asn Pro Ile Glu Asn Ser Pro Gly Asn Val Val Arg Ser Lys Gly 515 520 525 Leu Ser Val Phe Leu Asn Arg Ala Lys Ala Val Phe Phe Pro Gly Asn 530 535 540 Gln Glu Lys Asp Pro Leu Leu Lys Asn Gln Glu Phe Lys Gly Val Ser 545 550 555 560 (2) INFORMATION FOR SEQ ID NO: 91: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2669 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 91: CAGATGCCAG AAGAACACTG TTGCTCTTGG TGGACGGGCC CAGAGGAATT CAGAGTTAAA 60 CCTTGAGTGC CTGCGTCCGT GAGAATTCAG CATGGAATGT CTCTACTATT TCCTGGGATT 120 TCTGCTCCTG GCTGCAAGAT TGCCACTTGA TGCCGCCAAA CGATTTCATG ATGTGCTGGG 180 CAATGAAAGA CCTTCTGCTT ACATGAGGGA GCACAATCAA TTAAATGGCT GGTCTTCTGA 240 TGAAAATGAC TGGAATGAAA AACTCTACCC AGTGTGGAAG CGGGGAGACA TGAGGTGGAA 300 AAACTCCTGG AAGGGAGGCC GTGTGCAGGC GGTCCTGACC AGTGACTCAC CAGCCCTCGT 360 GGGCTCAAAT ATAACATTTG CGGTGAACCT GATATTCCCT AGATGCCAAA AGGAAGATGC 420 CAATGGCAAC ATAGTCTATG AGAAGAACTG CAGAAATGAG GCTGGTTTAT CTGCTGATCC 480 ATATGTTTAC AACTGGACAG CATGGTCAGA GGACAGTGAC GGGGAAAATG GCACCGGCCA 540 AAGCCATCAT AACGTCTTCC CTGATGGGAA ACCTTTTCCT CACCACCCCG GATGGAGAAG 600 ATGGAATTTC ATCTACGTCT TCCACACACT TGGTCAGTAT TTCCAGAAAT TGGGACGATG 660 TTCAGTGAGA GTTTCTGTGA ACACAGCCAA TGTGACACTT GGGCCTCAAC TCATGGAAGT 720 GACTGTCTAC AGAAGACATG GACGGGCATA TGTTCCCATC GCACAAGTGA AAGATGTGTA 780 CGTGGTAACA GATCAGATTC CTGTGTTTGT GACTATGTTC CAGAAGAACG ATCGAAATTC 840 ATCCGACGAA ACCTTCCTCA AAGATCTCCC CATTATGTTT GATGTCCTGA TTCATGATCC 900 TAGCCACTTC CTCAATTATT CTACCATTAA CTACAAGTGG AGCTTCGGGG ATAATACTGG 960 CCTGTTTGTT TCCACCAATC ATACTGTGAA TCACACGTAT GTGCTCAATG GAACCTTCAG 1020 CCTTAACCTC ACTGTGAAAG CTGCAGCACC AGGACCTTGT CCGCCACCGC CACCACCACC 1080 CAGACCTTCA AAACCCACCC CTTCTTTAGG ACCTGCTGGT GACAACCCCC TGGAGCTGAG 1140 TAGGATTCCT GATGAAAACT GCCAGATTAA CAGATATGGC CACTTTCAAG CCACCATCAC 1200 AATTGTAGAG GGAATCTTAG AGGTTAACAT CATCCAGATG ACAGACGTCC TGATGCCGGT 1260 GCCATGGCCT GAAAGCTCCC TAATAGACTT TGTCGTGACC TGCCAAGGGA GCATTCCCAC 1320 GGAGGTCTGT ACCATCATTT CTGACCCCAC CTGCGAGATC ACCCAGAACA CAGTCTGCAG 1380 CCCTGTGGAT GTGGATGAGA TGTGTCTGCT GACTGTGAGA CGAACCTTCA ATGGGTCTGG 1440 GACGTACTGT GTGAACCTCA CCCTGGGGGA TGACACAAGC CTGGCTCTCA CGAGCACCCT 1500 GATTTCTGTT CCTGACAGAG ACCCAGCCTC GCCTTTAAGG ATGGCAAACA GTGCCCTGAT 1560 CTCCGTTGGC TGCTTGGCCA TATTTGTCAC TGTGATCTCC CTCTTGGTGT ACAAAAAACA 1620 CAAGGAATAC AACCCAATAG AAAATAGTCC TGGGAATGTG GTCAGAAGCA AAGGCCTGAG 1680 TGTCTTTCTC AACCGTGCAA AAGCCGTGTT CTTCCCGGGA AACCAGGAAA AGGATCCGCT 1740 ACTCAAAAAC CAAGAATTTA AAGGAGTTTC TTAAATTTCG ACCTTGTTTC TGAAGCTCAC 1800 TTTTCAGTGC CATTGATGTG AGATGTGCTG GAGTGGCTAT TAACCTTTTT TTCCTAAAGA 1860 TTATTGTTAA ATAGATATTG TGGTTTGGGG AAGTTGAATT TTTTATAGGT TAAATGTCAT 1920 TTTAGAGATG GGGAGAGGGA TTATACTGCA GGCAGCTTCA GCCATGTTGT GAAACTGATA 1980 AAAGCAACTT AGCAAGGCTT CTTTTCATTA TTTTTTATGT TTCACTTATA AAGTCTTAGG 2040 TAACTAGTAG GATAGAAACA CTGTGTCCCG AGAGTAAGGA GAGAAGCTAC TATTGATTAG 2100 AGCCTAACCC AGGTTAACTG CAAGAAGAGG CGGGATACTT TCAGCTTTCC ATGTAACTGT 2160 ATGCATAAAG CCAATGTAGT CCAGTTTCTA AGATCATGTT CCAAGCTAAC TGAATCCCAC 2220 TTCAATACAC ACTCATGAAC TCCTGATGGA ACAATAACAG GCCCAAGCCT GTGGTATGAT 2280 GTGCACACTT GCTAGACTCA GAAAAAATAC TACTCTCATA AATGGGTGGG AGTATTTTGG 2340 TGACAACCTA CTTTGCTTGG CTGAGTGAAG GAATGATATT CATATATTCA TTTATTCCAT 2400 GGACATTTAG TTAGTGCTTT TTATATACCA GGCATGATGC TGAGTGACAC TCTTGTGTAT 2460 ATTTCCAAAT TTTTGTATAG TCGCTGCACA TATTTGAAAT CATATATTAA GACTTTCCAA 2520 AGATGAGGTC CCTGGTTTTT CATGGCAACT TGATCAGTAA GGATTTCACC TCTGTTTGTA 2580 ACTAAAACCA TCTACTATAT GTTAGACATG ACATTCTTTT TCTCTCCTTC CTGAAAAATA 2640 AAGTGTGGGA AGAGACAAAA AAAAAAAAA 2669 (2) INFORMATION FOR SEQ ID NO: 92: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 92: AAGGTGAAAG ATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGC CTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 93: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 262 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 93: AAGGTGAAAG ATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCT TA 262 (2) INFORMATION FOR SEQ ID NO: 94: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94: AAGGTGAAAG ATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGC CTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 95: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 190 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95: TACGAAGGTG GAGGCGGAGT CGAAGGCGAA GGGGGAGGGC ATGGCCCGGG CACTGCAGTT 60 TGCACGGTGA GGTTAAGGTT GAAGGTTCCA TTGAGCACAT AAGTGTGATT CAAAGTGTGA 120 TTGTTGGAGA CAAACAGGCC AGTGTTGTCC CCAAAGTTCC ACTTGTAGGA AATGGCAGAG 180 TCGTTGAGGA 190 (2) INFORMATION FOR SEQ ID NO: 96: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 96: AAGGTGAAAG ATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGC CTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 97: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 74 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 97: Arg Arg Trp Arg Arg Ser Arg Arg Arg Arg Gly Arg Ala Trp Gly His 1 5 10 15 Cys Ser His Gly Val Lys Val Gly Ser His Ser Val Ser Val Val Gly 20 25 30 Asp Lys Ala Ser Val Val Lys Val Val Gly Asn Gly Arg Val Val Val 35 40 45 Ala Gly Met Asn Asp Asp Asp Gly Val Ser Asp Arg Val Val Gly His 50 55 60 Gly His Tyr Arg Asp Cys Tyr His His His 65 70 (2) INFORMATION FOR SEQ ID NO: 98: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 71 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 98: Lys Val Lys Asp Val Tyr Val Thr Asp Val Val Thr Met Ser Lys Asn 1 5 10 15 Asp Arg Asn Ser Asp Arg Asp Val Asp Val His Asp Ser His Asn Asp 20 25 30 Ser Ala Ser Tyr Lys Trp Asn Gly Asp Asn Thr Gly Val Ser Asn Asn 35 40 45 His Thr Asn His Thr Tyr Val Asn Gly Thr Asn Asn Thr Val Thr Ala 50 55 60 Val Gly Cys Ser Ser Thr Ser 65 70 (2) INFORMATION FOR SEQ ID NO: 99: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 75 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 99: Tyr Gly Gly Gly Gly Val Gly Gly Gly Gly His Gly Gly Thr Ala Val 1 5 10 15 Cys Thr Val Arg Arg Lys Val Ser Thr Val Lys Val Thr Asn Arg Val 20 25 30 Ser Lys His Met Ala Ser Arg Lys Trp Gly Ser Met Arg Thr Ser Lys 35 40 45 Thr Met Gly Arg Ser Arg Lys Ser Ser Asp Lys Ser Trp Asp Met Val 50 55 60 Thr Asn Thr Gly Ser Val Thr Tyr Thr Ser Thr 65 70 75 (2) INFORMATION FOR SEQ ID NO: 100: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 100: Met Cys Tyr Tyr Gly Ala Ala Arg Asp Ala Ala Lys Arg His Asp Val 1 5 10 15 Gly Asn Arg Ser Ala Tyr Met Arg His Asn Asn Gly Trp Ser Ser Asp 20 25 30 Asn Asp Trp Asn Lys Tyr Val Trp Lys Arg Gly Asp Met Arg Trp Lys 35 40 45 Asn Ser Trp Lys Gly Gly Arg Val Ala Val Thr Ser Asp Ser Ala Val 50 55 60 Gly Ser Asn Thr Ala Val Asn Arg Cys Lys Asp Ala Asn Gly Asn Val 65 70 75 80 Tyr Lys Asn Cys Arg Asn Ala Gly Ser Ala Asp Tyr Val Tyr Asn Trp 85 90 95 Thr Ala Trp Ser Asp Ser Asp Gly Asn Gly Thr Gly Ser His His Asn 100 105 110 Val Asp Gly Lys His His Gly Trp Arg Arg Trp Asn Tyr Val His Thr 115 120 125 Gly Tyr Lys Gly Arg Cys Ser Val Arg Val Ser Val Asn Thr Ala Asn 130 135 140 Val Thr Gly Met Val Thr Val Tyr Arg Arg His Gly Arg Ala Tyr Val 145 150 155 160 Ala Val Lys Asp Val Tyr Val Val Thr Asp Val Val Thr Met Lys Asn 165 170 175 Asp Arg Asn Ser Ser Asp Thr Lys Asp Met Asp Val His Asp Ser His 180 185 190 Asn Tyr Ser Thr Asn Tyr Lys Trp Ser Gly Asp Asn Thr Gly Val Ser 195 200 205 Thr Asn His Thr Val Asn His Thr Tyr Val Asn Gly Thr Ser Asn Thr 210 215 220 Val Lys Ala Ala Ala Gly Cys Arg Ser Lys Thr Ser Gly Ala Gly Asp 225 230 235 240 Asn Ser Arg Asp Asn Cys Asn Arg Tyr Gly His Ala Thr Thr Val Gly 245 250 255 Val Asn Met Thr Asp Val Met Val Trp Ser Ser Asp Val Val Thr Cys 260 265 270 Gly Ser Thr Val Cys Thr Ser Asp Thr Cys Thr Asn Thr Val Cys Ser 275 280 285 Val Asp Val Asp Met Cys Thr Val Arg Arg Thr Asn Gly Ser Gly Thr 290 295 300 Tyr Cys Val Asn Thr Gly Asp Asp Thr Ser Ala Thr Ser Thr Ser Val 305 310 315 320 Asp Arg Asp Ala Ser Arg Met Ala Asn Ser Ala Ser Val Gly Cys Ala 325 330 335 Val Thr Val Ser Val Tyr Lys Lys His Lys Tyr Asn Asn Ser Gly Asn 340 345 350 Val Val Arg Ser Lys Gly Ser Val Asn Arg Ala Lys Ala Val Gly Asn 355 360 365 Lys Asp Lys Asn Lys Gly Val Ser 370 375 (2) INFORMATION FOR SEQ ID NO: 101: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2669 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 101: CAGATGCCAG AAGAACACTG TTGCTCTTGG TGGACGGGCC CAGAGGAATT CAGAGTTAAA 60 CCTTGAGTGC CTGCGTCCGT GAGAATTCAG CATGGAATGT CTCTACTATT TCCTGGGATT 120 TCTGCTCCTG GCTGCAAGAT TGCCACTTGA TGCCGCCAAA CGATTTCATG ATGTGCTGGG 180 CAATGAAAGA CCTTCTGCTT ACATGAGGGA GCACAATCAA TTAAATGGCT GGTCTTCTGA 240 TGAAAATGAC TGGAATGAAA AACTCTACCC AGTGTGGAAG CGGGGAGACA TGAGGTGGAA 300 AAACTCCTGG AAGGGAGGCC GTGTGCAGGC GGTCCTGACC AGTGACTCAC CAGCCCTCGT 360 GGGCTCAAAT ATAACATTTG CGGTGAACCT GATATTCCCT AGATGCCAAA AGGAAGATGC 420 CAATGGCAAC ATAGTCTATG AGAAGAACTG CAGAAATGAG GCTGGTTTAT CTGCTGATCC 480 ATATGTTTAC AACTGGACAG CATGGTCAGA GGACAGTGAC GGGGAAAATG GCACCGGCCA 540 AAGCCATCAT AACGTCTTCC CTGATGGGAA ACCTTTTCCT CACCACCCCG GATGGAGAAG 600 ATGGAATTTC ATCTACGTCT TCCACACACT TGGTCAGTAT TTCCAGAAAT TGGGACGATG 660 TTCAGTGAGA GTTTCTGTGA ACACAGCCAA TGTGACACTT GGGCCTCAAC TCATGGAAGT 720 GACTGTCTAC AGAAGACATG GACGGGCATA TGTTCCCATC GCACAAGTGA AAGATGTGTA 780 CGTGGTAACA GATCAGATTC CTGTGTTTGT GACTATGTTC CAGAAGAACG ATCGAAATTC 840 ATCCGACGAA ACCTTCCTCA AAGATCTCCC CATTATGTTT GATGTCCTGA TTCATGATCC 900 TAGCCACTTC CTCAATTATT CTACCATTAA CTACAAGTGG AGCTTCGGGG ATAATACTGG 960 CCTGTTTGTT TCCACCAATC ATACTGTGAA TCACACGTAT GTGCTCAATG GAACCTTCAG 1020 CCTTAACCTC ACTGTGAAAG CTGCAGCACC AGGACCTTGT CCGCCACCGC CACCACCACC 1080 CAGACCTTCA AAACCCACCC CTTCTTTAGG ACCTGCTGGT GACAACCCCC TGGAGCTGAG 1140 TAGGATTCCT GATGAAAACT GCCAGATTAA CAGATATGGC CACTTTCAAG CCACCATCAC 1200 AATTGTAGAG GGAATCTTAG AGGTTAACAT CATCCAGATG ACAGACGTCC TGATGCCGGT 1260 GCCATGGCCT GAAAGCTCCC TAATAGACTT TGTCGTGACC TGCCAAGGGA GCATTCCCAC 1320 GGAGGTCTGT ACCATCATTT CTGACCCCAC CTGCGAGATC ACCCAGAACA CAGTCTGCAG 1380 CCCTGTGGAT GTGGATGAGA TGTGTCTGCT GACTGTGAGA CGAACCTTCA ATGGGTCTGG 1440 GACGTACTGT GTGAACCTCA CCCTGGGGGA TGACACAAGC CTGGCTCTCA CGAGCACCCT 1500 GATTTCTGTT CCTGACAGAG ACCCAGCCTC GCCTTTAAGG ATGGCAAACA GTGCCCTGAT 1560 CTCCGTTGGC TGCTTGGCCA TATTTGTCAC TGTGATCTCC CTCTTGGTGT ACAAAAAACA 1620 CAAGGAATAC AACCCAATAG AAAATAGTCC TGGGAATGTG GTCAGAAGCA AAGGCCTGAG 1680 TGTCTTTCTC AACCGTGCAA AAGCCGTGTT CTTCCCGGGA AACCAGGAAA AGGATCCGCT 1740 ACTCAAAAAC CAAGAATTTA AAGGAGTTTC TTAAATTTCG ACCTTGTTTC TGAAGCTCAC 1800 TTTTCAGTGC CATTGATGTG AGATGTGCTG GAGTGGCTAT TAACCTTTTT TTCCTAAAGA 1860 TTATTGTTAA ATAGATATTG TGGTTTGGGG AAGTTGAATT TTTTATAGGT TAAATGTCAT 1920 TTTAGAGATG GGGAGAGGGA TTATACTGCA GGCAGCTTCA GCCATGTTGT GAAACTGATA 1980 AAAGCAACTT AGCAAGGCTT CTTTTCATTA TTTTTTATGT TTCACTTATA AAGTCTTAGG 2040 TAACTAGTAG GATAGAAACA CTGTGTCCCG AGAGTAAGGA GAGAAGCTAC TATTGATTAG 2100 AGCCTAACCC AGGTTAACTG CAAGAAGAGG CGGGATACTT TCAGCTTTCC ATGTAACTGT 2160 ATGCATAAAG CCAATGTAGT CCAGTTTCTA AGATCATGTT CCAAGCTAAC TGAATCCCAC 2220 TTCAATACAC ACTCATGAAC TCCTGATGGA ACAATAACAG GCCCAAGCCT GTGGTATGAT 2280 GTGCACACTT GCTAGACTCA GAAAAAATAC TACTCTCATA AATGGGTGGG AGTATTTTGG 2340 TGACAACCTA CTTTGCTTGG CTGAGTGAAG GAATGATATT CATATATTCA TTTATTCCAT 2400 GGACATTTAG TTAGTGCTTT TTATATACCA GGCATGATGC TGAGTGACAC TCTTGTGTAT 2460 ATTTCCAAAT TTTTGTATAG TCGCTGCACA TATTTGAAAT CATATATTAA GACTTTCCAA 2520 AGATGAGGTC CCTGGTTTTT CATGGCAACT TGATCAGTAA GGATTTCACC TCTGTTTGTA 2580 ACTAAAACCA TCTACTATAT GTTAGACATG ACATTCTTTT TCTCTCCTTC CTGAAAAATA 2640 AAGTGTGGGA AGAGACAAAA AAAAAAAAA 2669 (2) INFORMATION FOR SEQ ID NO: 102: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 376 amino acids (B) TYPE: amino acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: peptide (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: N-terminal (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 102: Met Cys Tyr Tyr Gly Ala Ala Arg Asp Ala Ala Lys Arg His Asp Val 1 5 10 15 Gly Asn Arg Ser Ala Tyr Met Arg His Asn Asn Gly Trp Ser Ser Asp 20 25 30 Asn Asp Trp Asn Lys Tyr Val Trp Lys Arg Gly Asp Met Arg Trp Lys 35 40 45 Asn Ser Trp Lys Gly Gly Arg Val Ala Val Thr Ser Asp Ser Ala Val 50 55 60 Gly Ser Asn Thr Ala Val Asn Arg Cys Lys Asp Ala Asn Gly Asn Val 65 70 75 80 Tyr Lys Asn Cys Arg Asn Ala Gly Ser Ala Asp Tyr Val Tyr Asn Trp 85 90 95 Thr Ala Trp Ser Asp Ser Asp Gly Asn Gly Thr Gly Ser His His Asn 100 105 110 Val Asp Gly Lys His His Gly Trp Arg Arg Trp Asn Tyr Val His Thr 115 120 125 Gly Tyr Lys Gly Arg Cys Ser Val Arg Val Ser Val Asn Thr Ala Asn 130 135 140 Val Thr Gly Met Val Thr Val Tyr Arg Arg His Gly Arg Ala Tyr Val 145 150 155 160 Ala Val Lys Asp Val Tyr Val Val Thr Asp Val Val Thr Met Lys Asn 165 170 175 Asp Arg Asn Ser Ser Asp Thr Lys Asp Met Asp Val His Asp Ser His 180 185 190 Asn Tyr Ser Thr Asn Tyr Lys Trp Ser Gly Asp Asn Thr Gly Val Ser 195 200 205 Thr Asn His Thr Val Asn His Thr Tyr Val Asn Gly Thr Ser Asn Thr 210 215 220 Val Lys Ala Ala Ala Gly Cys Arg Ser Lys Thr Ser Gly Ala Gly Asp 225 230 235 240 Asn Ser Arg Asp Asn Cys Asn Arg Tyr Gly His Ala Thr Thr Val Gly 245 250 255 Val Asn Met Thr Asp Val Met Val Trp Ser Ser Asp Val Val Thr Cys 260 265 270 Gly Ser Thr Val Cys Thr Ser Asp Thr Cys Thr Asn Thr Val Cys Ser 275 280 285 Val Asp Val Asp Met Cys Thr Val Arg Arg Thr Asn Gly Ser Gly Thr 290 295 300 Tyr Cys Val Asn Thr Gly Asp Asp Thr Ser Ala Thr Ser Thr Ser Val 305 310 315 320 Asp Arg Asp Ala Ser Arg Met Ala Asn Ser Ala Ser Val Gly Cys Ala 325 330 335 Val Thr Val Ser Val Tyr Lys Lys His Lys Tyr Asn Asn Ser Gly Asn 340 345 350 Val Val Arg Ser Lys Gly Ser Val Asn Arg Ala Lys Ala Val Gly Asn 355 360 365 Lys Asp Lys Asn Lys Gly Val Ser 370 375 (2) INFORMATION FOR SEQ ID NO: 103: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 103: CTGACCAGGA ACCCACTCTT CTGTGCATGT ATGTGAGCTG TGCAGAAGTA TGTGGCTGGG 60 AACTGTTGTT CTCTAAGGAT TATTGTAAAA TGTATATCGT GGCTTAGGGA GTGTGGTTAA 120 ATAGCATTTT AGAGAAGAAA AAAAAAAAAA AAAAAACTCG AGAGTACTTC TAGAGCGGCC 180 GCGGCGCCAT CGATTTTCCA CCCGGGTGGG GTACCAGGTA AGTGTACCCA ATTCGCCTAT 240 AGTGAGT 247 (2) INFORMATION FOR SEQ ID NO: 104: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 363 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 104: AGGACAAGCC AAGGACACTC TAAGTCTTTG GCCTTCCCTC TGACCAGGAA CCCACTCTTC 60 TGTGCATGTA TGTGAGCTGT GCAGAAGTAT GTGGCTGGGA ACTGTTGTTC TCTAAGGATT 120 ATTGTAAAAT GTATATCGTG GCTTAGGGAG TGTGGTTAAA TAGCATTTTA GAGAAGACAT 180 GGGAAGACTT AGTGTTTCTT CCCATCTGTA TTGTGGTTTT TACACTGTTC GTGGGGTGGA 240 CACGCTGTGT CTGAAGGGGA GGTGGGGGTC ACTGCTACTT AAGGTCCTAG GTTAACTGGG 300 GGAGATACCA CAGATGCTCA GCTTTCCACA TAACATGGGC ATGAACCAGC TAATCACACT 360 GAA 363 (2) INFORMATION FOR SEQ ID NO: 105: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 524 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 105: GGATCCTTCT CCTGGTCTCC TCGGAAGAAC GGGGCTTTCG CGTGACTGAG GAGAACACTC 60 AGGCCCTTGC CCTTGACCGT GTTCCTGGGG CAGTTTCCTA TTGGCTTGTA CGCCTTGTGT 120 TTTTTGTACA GCAAGATGGT AACCATGGTG ACAAGCACAG CCAGGCAGCC GATGGAGATC 180 AGGACACCAT TCACTGCTCT CAGAGGGAGT CTGGGTCTTT GCCAGGGATA GAGATCAGGG 240 TGCTGGTGAG GGCCAGGCTT CGATCATCTC CCAGAGTGAA ATTCACACAG TAGGTGCCAG 300 ACCCATTGAA GGCTCTTCTC ACAGACAGCA GCACAGCCCA TCCACAGCCA CAGGGCTGCA 360 GACCCGGTTC TGGGCGATCT GGCAGGTGGG GTCGGAGATG ATCGTACAGG CTTCCATGGG 420 GGTGGCCCCT TTGCAGGTCA CAGTGAAGTC CATCAGGGAG TTGGCAGGCT GCGGTGTGGG 480 CATGGGGACA TCTGCTATCT GCATGATGCT GACTTCCAGG ATCC 524 (2) INFORMATION FOR SEQ ID NO: 106: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 309 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 106: TAGCAGATGT CCCCATGCCC ACACCGCAGC CTGCCAACTC CCTGATGGAC TTCACTGTGA 60 CCTGCAAAGG GGCCACCCCC ATGGAAGCCT GTACGATCAT CTCCGACCCC ACCTGCCAGA 120 TCGCCCAGAA CCGGGTCTGC AGCCCTGTGG CTGTGGATGG GCTGTGCTGC TGTCTGTGAG 180 AAGAGCCTTC AATGGGTCTG GCACCTACTG TGTGAATTTC ACTCTGGGAG ATGATCGAAG 240 CCTGGCCCTC ACCAGCACCC TGATCTCTAT CCCTGGCAAA GACCCAGACT CCCTCTGAGA 300 GCAGTGAAT 309 (2) INFORMATION FOR SEQ ID NO: 107: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 292 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 107: GGATCCTTCT CCTGGTCTCC TCGGAAGAAC GGGGCTTTCG CGTGACTGAG GAGAACACTC 60 AGGCCCTTGC CCTTGACCGT GTTCCTGGGG CAGTTTCCTA TTGGCTTGTA CGCCTTGTGT 120 TTTTTGTACA GCAAGATGGT AACCATGGTG ACAAGCACAG CCAGGCAGCC GATGGAGATC 180 AGGACACCAT TCACTGCTCT CAGAGGGAGT CTGGGTCTTT GCCAGGGATA GAGATCAGGG 240 TGCTGGTGAG GGCCAGGCTT CGATCATCTC CCAGAGTGAA ATTCACACAG TA 292 (2) INFORMATION FOR SEQ ID NO: 108: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 108: TTTTTTTTTT TTTTTTTTAG ACTGCCTTTT TAATGAGTAG AATATGTACA CACACGCACC 60 ATACACAAAG CCCGGGCCCA TTATAATTTT GTCAGGAGCT CAGGCATGCT CAGTGAGTTG 120 GAAGGCAGAT GAAGCATGCC TTCAGGTGGT GATTAGCTGG GTTCATGCCC ATGTTATCGT 180 GGAAAGCTGA GGCATCTGTG GTATCTCCCC CAGTTAACCT AGGACCTTAA GTAGCAGTGA 240 CCCACCTCCC TTCAGACACA GCG 263 (2) INFORMATION FOR SEQ ID NO: 109: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 109: GGATCCTGGA AGTCAGCATC ATGCAGATAG CAGATGTCCC CATGCCCACA CCGCAGCCTG 60 CCAACTCCCT GATGGACTTC ACTGTGACCT GCAAAGGGGC CACCCCCATG GAAGCCTGTA 120 CGATCATCTC CGACCCCACC TGCCAGATCG CCCAGAACCG GGTCTGCAGC CCTGTGGCTG 180 TGGATGGGCT GTGCTGCTGT CTGTGAGAAG AGCCTTCAAT GGGTCTGGCA CCTACTGTGT 240 GAATTTCACT CTGGGAGATG ATCGAAGCCT 270 (2) INFORMATION FOR SEQ ID NO: 110: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 239 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 110: TTTTTTTTTT TTTTTTTTTC TTCTCTAAAA TGCTATTTAA CCACACTCCC TAAGCCACGA 60 TATACATTTT ACAATAATCC TTAGAGAACA ACAGTTCCCA GCCACATACT TCTGCACAGC 120 TCACATACAT GCACAGAAGA GTGGGTTCCT GGTCAGAGGG AAGGCCAAAG ACTTAGAGTG 180 TCCTTGGCTT GTCTGGAGCA ATGGATCCTT CTCCTGGTCT CCTCGGAAGA ACGGGCTTT 239 (2) INFORMATION FOR SEQ ID NO: 111: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 111: AAACTGCAGT GCCCGGGCCA TGCCCTCCCC CTTCGCCTTC GACTCCGCCT CCACCTTCAA 60 CTCCGCCCTC ACCTCCGCCC TCACCTCTGC CCACATTATC AACACCTAGC CCCTCTTTAA 120 TGCCTACTGG TTACAAATCC ATGGAGCTGA GTGACATTTC CAATGAAAAC TGCCGAATAA 180 ACAGATATGG CTACTTCAGA GCCACCATCA CAATTGTAGA GGGGATCCTG GACGCAGCAT 240 CATGCAGATA GCAGATGTCC CATGCCCACA CCGCAGCCGT CCAACTCCTG ATGGACTTCA 300 CTGTGACCTC AAGGGCACCC ATGGAAGCTG TCAGA 335 (2) INFORMATION FOR SEQ ID NO: 112: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 217 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 112: CCTCAACGAC TCTGCCATTT CCTACAAGTG GAACTTTGGG GACAACACTG GCCTGTTTGT 60 CTCCAACAAT CACACTTTGA ATCACACTTA TGTGCTCAAT GGAACCTTCA ACCTTAACCT 120 CACCGTGCAA ACTGCAGTGC CCGGGCCATG CCCTCCCCCT TCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACT CCGCCCTCAC CTCCGCCCTC ACCTCTG 217 (2) INFORMATION FOR SEQ ID NO: 113: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 620 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 113: CCTCAACGAC TCTGCCATTT CCTACAAGTG GAACTTTGGG GACAACACTG GCCTGTTTGT 60 CTCCAACAAT CACACTTTGA ATCACACTTA TGTGCTCAAT GGAACCTTCA ACCTTAACCT 120 CACCGTGCAA ACTGCAGTGC CCGGGCCATG CCCTCCCCCT TCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACT CCGCCCTCAC CTCCGCCCTC ACCTCTGCCC ACATTATCAA CACCTAGCCC 240 CTCTTTAATG CCTACTGGTT ACAAATCCAT GGAGCTGAGT GACATTTCCA ATGAAAACTG 300 CCGAATAAAC AGATATGGCT ACTTCAGAGC CACCATCACA ATTGTAGAGG GGATCCTGGA 360 AGTCAGCATC ATGCAGATAG CAGATGTCCC CATGCCCACA CCGCAGCCTG CCAACTCCCT 420 GATGGACTTC ACTGTGACCT GCAAAGGGGC CACCCCCATG GAAGCCTGTA CGATCATCTC 480 CGACCCCACC TGCCAGATCG CCCAGAACCG GGTCTGCAGC CCTGTGGCTG TGGATGGGCT 540 GTGCTGCTGT CTGTGAGAAG AGCCTTCAAT GGGTCTGGCA CCTACTGTGT GAATTTCACT 600 CTGGGAGATG ATGCAAGCCT 620 (2) INFORMATION FOR SEQ ID NO: 114: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 354 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 114: GGATCCCCTC TACAATTGTG ATGGTGGCTC TGAAGTAGCC ATATCTGTTT ATTCGGCAGT 60 TTTCATTGGA AATGTCACTC AGCTCCATGG ATTTGTAACC AGTAGGCATT AAAGAGGGGC 120 TAGGTGTTGA TAATGTGGGC AGAGGTGAGG GCGGAGGTGA GGGCGGAGTT GAAGGTGGAG 180 GCGGAGTCGA AGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC ACGGTGAGGT 240 TAAGGTTGAA GGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG TTGGAGACAA 300 ACAGGCCAGT GTTGTCCCAA AGTTCCACTT GTAGGAATGG CAGAGTCGTT GAGG 354 (2) INFORMATION FOR SEQ ID NO: 115: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 473 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 115: CCTCAACGAC TCTGCCATTT CCTACAAGTG GAACTTTGGG GACAACACTG GCCTGTTTGT 60 CTCCAACAAT CACACTTTGA ATCACACTTA TGTGCTCAAT GGAACCTTCA ACCTTAACCT 120 CACCGTGCAA ACTGCAGTGC CCGGGCCATG CCCTCCCCCT TCGCCTTCGA CTCCGCCTCC 180 ACCTTCAACT CCGCCCTCAC CTCCGCCCTC ACCTCTGCCC ACATTATCAA CACCTAGCCC 240 CTCTTTAATG CCTACTGGTT ACAAATCCAT GGAGCTGAGT GACATTTCCA ATGAAAACTG 300 CCGAATAAAC AGATATGGCT ACTTCAGAGC CACCATCACA ATTGTAGAGG GGATCCTGGA 360 AGTCAGCATC ATGCAGATAG CAGATGTCCC CATGCCCACA CCGCAGCCTG CCAACTCCCT 420 GATGGACTTC ACTGTGACCT GCAAAGGGGC CACCCCCATG GAAGCCTGTA CGA 473 (2) INFORMATION FOR SEQ ID NO: 116: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 223 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 116: GAAGGTGGAG GCGGAGTCGA AGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC 60 ACGGTGAGGT TAAGGTTGAA GGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG 120 TTGGAGACAA ACAGGCCAGT GTTGTCCCCA AAGTTCCACT TGTAGGAAAT GGCAGAGTCG 180 TTGAGGAAGT GGCTGGGATC ATGAATGAGG ACATCGAAGA CGA 223 (2) INFORMATION FOR SEQ ID NO: 117: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 247 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 117: GAATTCGCAC GAGGGGAGTC AGAGTCAAGC CCTGACTGGT TGCAGGCGCT CGGAGTCAGC 60 ATGGAAAGTC TCTGCGGGGT CCTGGGATTT CTGCTGCTGG CTGCAGGACT GCCTCTCCAG 120 GCTGCCAAGC GATTTCGTGA TGTGCTGGGC CATGAACAGT ATCCCGATCA CATGAGAGAG 180 CACAACCAAT TACGTGGCTG GTCTTCGGAT GAAAATGAAT GGGTTCCAAT ATCACTTTTG 240 TGGTGAA 247 (2) INFORMATION FOR SEQ ID NO: 118: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 118: GAATTCGGCA CGAGGAAGGA GGCCGTGTGC AGGCAGTCCT GACCAGTGAC TCACCGGCTC 60 TGGTGGGTTC CAATATCACT TTTGTGGTGA ACCTGGTGTT CCCCAGATGC CAGAAGGAAG 120 ATGCTAATGG CAATATCGTC TATGAGAAGA ACTGCAGGAA TGATTTGGGA CTGACATCTG 180 ACCTGCATGT CTACAACTGG ACTGCAGGGG CAGATGATGG TGACTGGGAA GATGGCACCT 240 (2) INFORMATION FOR SEQ ID NO: 119: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 119: GAAGGTGGAG GCGGAGTCGA AGGCGAAGGG GGAGGGCATG GCCCGGGCAC TGCAGTTTGC 60 ACGGTGAGGT TAAGGTTGAA GGTTCCATTG AGCACATAAG TGTGATTCAA AGTGTGATTG 120 TTGGAGACAA ACAGGCCAGT GTTGTCCCCA AAGTTCCACT TGTAGGAAAT GGCAGAGTCG 180 TTGAGGAAGT GGCTGGGATC ATGAATGAGG ACATCGAAGA CGATGGGGAG GTCTCTGAGG 240 AAGATCTCAT CAGACAAGTT 260 (2) INFORMATION FOR SEQ ID NO: 120: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 231 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 120: GAATTCGGCA CGAGGTCAAG CCCTGACTGG TTGCAGGCGC TCGGAGTCAG CATGGAAAGT 60 CTCTGCGGGG TCCTGGGATT TCTGCTGCTG GCTGCAGGAC TGCCTCTCCA GGCTGCCAAG 120 CGATTTCGTG ATGTGCTGGG CCATGAACAG TATCCCGATC ACATGAGAGA GCACAACCAA 180 TTACGTGGCT GGTCTTCGGA TGAAAATGAA TGGATGAACA CCTTGTATCC A 231 (2) INFORMATION FOR SEQ ID NO: 121: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 286 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 121: AAGGGGGAGG GCATGGCCCG GGCACTGCAG TTTGCACGGT GAGGTTAAGG TTGAAGGTTC 60 CATTGAGCAC ATAAGTGTGA TTCAAAGTGT GATTGTTGGA GACAAACAGG CCAGTGTTGT 120 CCCCAAAGTT CCACTTGTAG GAAATGGCAG AGTCGTTGAG GAAGTGGCTG GGATCATGAA 180 TGAGGACATC GAAGACGATG GGGAGGTCTC TGAGGAAGAT CTCATCAGAC AAGTTCCTGT 240 CATTCTTCTG GGACATGGTC ACGAATACAG GGATCTGATC TGTTAT 286 (2) INFORMATION FOR SEQ ID NO: 122: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 224 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 122: GAATTCGGCA CGAGCCGACA CTGTGACTCC TGGTGGATGG GACTGGGGAG TCAGAGTCAA 60 GCCCTGACTG GTTGCAGGCG CTCGGAGTCA GCATGGAAAG TCTCTGCGGG GTCCTGGGAT 120 TTCTGCTGCT GGCTGCAGGA CTGCCTCTCC AGGCTGCCAA GCGATTTCGT GATGTGCTGG 180 GCCATGAACA GTATCCCGAT CACATGAGAG AGCACAACCA ATTA 224 (2) INFORMATION FOR SEQ ID NO: 123: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 123: AAGGTGAAAG ATGTGTATGT GATAACAGAT CAGATCCCTG TATTCGTGAC CATGTCCCAG 60 AAGAATGACA GGAACTTGTC TGATGAGATC TTCCTCAGAG ACCTCCCCAT CGTCTTCGAT 120 GTCCTCATTC ATGATCCCAG CCACTTCCTC AACGACTCTG CCATTTCCTA CAAGTGGAAC 180 TTTGGGGACA ACACTGGCCT GTTTGTCTCC AACAATCACA CTTTGAATCA CACTTATGTG 240 CTCAATGGAA CCTTCAACCT TAACCTCACC GTGCAAACTG CAGTGCCCGG GCCATGCCCT 300 CCCCCTTCGC CTTCGACTCC GCCTCCACCT TCGTA 335 (2) INFORMATION FOR SEQ ID NO: 124: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 124: TACCATCGGA GAAAGAAGAC CAAGCAAGGC TCAGGCAGCC ACCGCCTGCT TCGCACTGAG 60 CCTCCTGACT CAGACTCAGA GTCCAGCACA GACGAAGAGG AATTTGGAGA ATTGGAAATC 120 GCTCTCGTTT TGTCAAGGGA GACTATCCCG ATGCTGCAAG ATCTGCTGTC CCTCTGGCCT 180 TTGTCATCCT CGCGCCTGCG TTGTGGCCTC TGTGGGCTTG GTGTGGAGCA AATGGCTCTC 240 AAGGAGGACT GAGTCTCAAG GAAATT 266 (2) INFORMATION FOR SEQ ID NO: 125: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 125: AGCTAAGGTC AGGAGGTGTC TGAAGAATTG GCTGATGCAT GGCAGGGATG TTGTTGACCT 60 GCTTTTAGAA CAATACTTCC ATTTAATTAT AGCATATCTT ATGTGTGTAT TAAAGCAGAG 120 CCGATCTGGT GGGGCTCATT AAGTAAATGT ACTTACTGCA AAAGGTTCAA CTGGTGACCC 180 CAGTTTTCCC CAGAAGCAAT ATGATAGGAC AGAGGCGACT CCTGCAAGTT GTCTCAGACT 240 TCACACATAC ATTGTGACAT TCTCTGAGCA TGTGCACTGT ACATGATATG ACACTATCAA 300 (2) INFORMATION FOR SEQ ID NO: 126: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 312 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 126: AGCTAAGGTC CACTACCTTG TGAAGATGTA TAAACACCTG AAATGTAGAA GCGATCCGTA 60 TGTCAAGATC GAGGGGAAGG ACGCTGACGA CTGGCTGTGT GTGGACTTTG GGAGTATGGT 120 GATCCATTTG ATGCTTCCAG AAACCAGAGA AACCTATGAA TTAGAGAAAC TATGGACTCT 180 ACGTTCTTTT GATGACCTTA GCTAAGCCGA ATCAGCACAC TGGCGGCGTT ACTAGTGGAT 240 CGAGCTCGTA CAGCTGATGC ATAGCTTGAG TATCTATAGG TTACTAATAG CTGGCTATCA 300 TGTCAAGCGT TC 312 (2) INFORMATION FOR SEQ ID NO: 127: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 281 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 127: GCTGAGCTGC AGAGAGTAGC ACATCCTTGC TAATTCAATA ACTACCAGTT TTTATTGGTG 60 AAACATGAAT CCAGATGGTA TGGTTGCTCT CCTGGACTAC CGTGAAGATG GTGTGACTCC 120 ATTCATGATT TTCTTTAAGG ATGGCTTAGA GATGGAGAAA TGTTAACAAA TTGGATCTAT 180 CACCTGTCAC CATAATTGGC TGCTGCTTAC CATCCATACA ACACCAGGAC TTAGGACAAA 240 TGGGACTGAT GTCATCTTGA GCTTTTATTT TGACCTTAGC T 281 (2) INFORMATION FOR SEQ ID NO: 128: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 295 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 128: AGCTAAGGTC AGAGCCAATA GTATCATGAG AACTGAAGAA GTAATAAAGC AACTTCTCCA 60 GAAATTTAAG ATTGAGAATA GCCCTCGGGA TTTCGCTCTT TACATTATTT TTGGGACAGG 120 AGAGCAGAGA AAGCTAAAGA AGACCGATGT CCACTGCTGC AGAGGTTACT ACAAGGACCA 180 TCCAAAAGCA ATGCTCGGAT CTCTCATGGA TAAAGATGCA GAAGAATCAC GAGAGATGTG 240 GCTCGTACAT TATTTCACTT TCTTCTGATC ATACTCAAGA TAGATGAGAG AGAAT 295 (2) INFORMATION FOR SEQ ID NO: 129: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 240 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 129: TTGACTTCTG AGTCTAACAC AGACACTGCA AGGGTTAATT TTCCAAGAGG TGGTTGTTGT 60 TGACGATAAA TTCATTAAGA ATTTTTAAAA ATTTAGTTAG ATTTACCAAA GTCACTGGAG 120 ACAAATTCAG AAGGCATATA TACCTGCCAG TTTTGTGGAC TACATTAATA GGGAGGCTTT 180 TATGTTTGAT GTAATTCTTA CAGTTCTAAG AATTAAGTTC CATTGCATGA GACCTTAGCT 240 (2) INFORMATION FOR SEQ ID NO: 130: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 196 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 130: AAGGTGAATC CCCGACGGCT CTGGGCCCGA GGAGAAGCGT CGCCGTGGCA AATTGGCACT 60 GCAGGAGAAG CCCTCCACAG GTACTTGGAA AAACTGGTCT CTGAGGCCAA GGCCAGCTCC 120 GAGACATTCA GGACTTCTGG ATCAGCCTCC AGGGACACTG TGCAGTGAGA AGATGGCCAT 180 GAGTCCTGCC AGTGAG 196 (2) INFORMATION FOR SEQ ID NO: 131: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 187 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 131: AATTTTTTTT TTCGACGGCC CAACGGGGGC TTGGTGGATG GAAATATGGT TTTGTGAGTT 60 ATTGCACTAC CTGGAATATC TATGCCTCTT ATTTGCGTGT ACTGTTGCTG CTGATCGTTT 120 GGTGCTGTGT GAGTGAACCT ATGGCTTAGA AAAACGACTT TGTCTTAAAC TGAGTGGGTG 180 TTCAGGG 187 (2) INFORMATION FOR SEQ ID NO: 132: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 197 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 132: CACCTGATTT AAAGGAAAAG CATTCTGACG TAAGAAGCTG AAAGGCGGCC CTTGCGTGCT 60 TTGAACTTTC TTATACAGCA CAGTCATCTG AAGCTTCCTG TGTGACCAAG ACAAGAACGC 120 GTGCACAAGA CTGAGAAACA GCAAGAAACA ACCCGGCATT CTACTTTCTC AACACTATCA 180 TACTTTAAAC CTTTCAC 197 (2) INFORMATION FOR SEQ ID NO: 133: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 133: CTAGCTTACG CTAGTCCCCC ATGCATAAAG ACTGATCGCT TTTCCTTAGA AAGGTGAGAG 60 GGTTAGGACA AGGCCGTGTG GTAACAACAC CCGCAGCTCG AAAAACCAAT GGCTTGTTAA 120 CGTGTCAGTG AGGCACTGTA CGGACGTCCA TAGTCCACAT CTTCAAATTC CCGCAGAAGG 180 CTTCCTATTC TTAAACTCTA 200 (2) INFORMATION FOR SEQ ID NO: 134: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 134: CTACATTTCT GTATCCATTC CTCTGTTGAA GGCTCTGGTT CTTTCCAGCT TCTGGCTATT 60 ATAAATAAGG CTGCTATAAA CACAGTGGAG GCATGTGTCC TTGTTATATT TTGGAGCATC 120 TTTTGGGTAT ATGCCCAGAA GTGCTATAGC TGGTTCCTCA GGTAGTACTA TGTCGAATTT 180 TCTGAGGAAC TGCCAGACTG ATTTCCAGAG TGGTTGTACC AGCTTGCAAT CCCACCAGCA 240 ATAGAGGAGT GTTCCTCTTT CTCTATATTC TTGCCAACAT CTGCTGTCAC CTGAGTGTTT 300 (2) INFORMATION FOR SEQ ID NO: 135: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 135: TGGTAAAGGG GGAATGATGT CGAGGCCATC CTGGGCTGTA GAGCCAGGCC CTGGCTTGGG 60 GAGTGGGCAT TGTTAACTTG TTGCTGACTT TGTGTTGACC CCTGCATCAG CAACTATTTC 120 CTTAAATCCA GGATACAACT TGTTAAGTGT GACAGCTTTC CTTTACACAC CATTTTTGTG 180 GGTGTATATA TATATTTGAC TTGGGGAGAA TTATTTTTTA CAAAAATACA AAATAGCTTT 240 TAA 243 (2) INFORMATION FOR SEQ ID NO: 136: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 136: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATT GGCTGGAAAG ATTACACTGC 60 CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTAC ATGAGAGTCT TAGTGCATGA 120 AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGAC CAAACCTACG CTGGTGGACG 180 GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCG GACCTCAAGT ATGAGTGCAG 240 AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2) INFORMATION FOR SEQ ID NO: 137: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 137: TGACCTACGT GTAGTTGGTG TGCTTGTTGT CGAAGATGAG GGCCTCCTGG ATGAGCTGGT 60 GCTGCTGCTC CAGCAGGTCC AGGCTGGGCT TGTAGTCCAC GAGTCTGCGC TCGTACTGCT 120 TCAGGTGGCT CAGCTGGTCT TCCAGAGTCC CGTTCATCTC AATGGAGATG CGCCCGATCT 180 CCTCCATCTT AGTCTGGATC CACGGCCCCA CCATATTGGC TTGGCTGGCG AACTGTCGGC 240 GAAGGCTGCA TTGGATTGCT 260 (2) INFORMATION FOR SEQ ID NO: 138: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 187 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 138: AATTTTTTTT TTCGACGGCC CAACGGGGGC TTGGTGGATG GAAATATGGT TTTGTGAGTT 60 ATTGCACTAC CTGGAATATC TATGCCTCTT ATTTGCGTGT ACTGTTGCTG CTGATCGTTT 120 GGTGCTGTGT GAGTGAACCT ATGGCTTAGA AAAACGACTT TGTCTTAAAC TGAGTGGGTG 180 TTCAGGG 187 (2) INFORMATION FOR SEQ ID NO: 139: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 197 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 139: CACCTGATTT AAAGGAAAAG CATTCTGACG TAAGAAGCTG AAAGGCGGCC CTTGCGTGCT 60 TTGAACTTTC TTATACAGCA CAGTCATCTG AAGCTTCCTG TGTGACCAAG ACAAGAACGC 120 GTGCACAAGA CTGAGAAACA GCAAGAAACA ACCCGGCATT CTACTTTCTC AACACTATCA 180 TACTTTAAAC CTTTCAC 197 (2) INFORMATION FOR SEQ ID NO: 140: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 140: CTAGCTTACG CTAGTCCCCC ATGCATAAAG ACTGATCGCT TTTCCTTAGA AAGGTGAGAG 60 GGTTAGGACA AGGCCGTGTG GTAACAACAC CCGCAGCTCG AAAAACCAAT GGCTTGTTAA 120 CGTGTCAGTG AGGCACTGTA CGGACGTCCA TAGTCCACAT CTTCAAATTC CCGCAGAAGG 180 CTTCCTATTC TTAAACTCTA 200 (2) INFORMATION FOR SEQ ID NO: 141: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 141: CTACATTTCT GTATCCATTC CTCTGTTGAA GGCTCTGGTT CTTTCCAGCT TCTGGCTATT 60 ATAAATAAGG CTGCTATAAA CACAGTGGAG GCATGTGTCC TTGTTATATT TTGGAGCATC 120 TTTTGGGTAT ATGCCCAGAA GTGCTATAGC TGGTTCCTCA GGTAGTACTA TGTCGAATTT 180 TCTGAGGAAC TGCCAGACTG ATTTCCAGAG TGGTTGTACC AGCTTGCAAT CCCACCAGCA 240 ATAGAGGAGT GTTCCTCTTT CTCTATATTC TTGCCAACAT CTGCTGTCAC CTGAGTGTTT 300 (2) INFORMATION FOR SEQ ID NO: 142: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 142: TGGTAAAGGG GGAATGATGT CGAGGCCATC CTGGGCTGTA GAGCCAGGCC CTGGCTTGGG 60 GAGTGGGCAT TGTTAACTTG TTGCTGACTT TGTGTTGACC CCTGCATCAG CAACTATTTC 120 CTTAAATCCA GGATACAACT TGTTAAGTGT GACAGCTTTC CTTTACACAC CATTTTTGTG 180 GGTGTATATA TATATTTGAC TTGGGGAGAA TTATTTTTTA CAAAAATACA AAATAGCTTT 240 TAA 243 (2) INFORMATION FOR SEQ ID NO: 143: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 270 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 143: AGCTAAGGTC CGGACTCTAT GGCATGACCC CAAAAACATT GGCTGGAAAG ATTACACTGC 60 CTACAGGTGG CACCTGATTC ACAGGCCTAA GACAGGCTAC ATGAGAGTCT TAGTGCATGA 120 AGGAAAGCAA GTCATGGCTG ACTCAGGACC AATTTATGAC CAAACCTACG CTGGTGGACG 180 GCTGGGCTGT TTGTCTTCTC CAAGAGATGG TCTATTCTCG GACCTCAAGT ATGAGTGCAG 240 AGATGCTAGA GAGCAGGCTC AGTCTCAGCA 270 (2) INFORMATION FOR SEQ ID NO: 144: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 260 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 144: TGACCTACGT GTAGTTGGTG TGCTTGTTGT CGAAGATGAG GGCCTCCTGG ATGAGCTGGT 60 GCTGCTGCTC CAGCAGGTCC AGGCTGGGCT TGTAGTCCAC GAGTCTGCGC TCGTACTGCT 120 TCAGGTGGCT CAGCTGGTCT TCCAGAGTCC CGTTCATCTC AATGGAGATG CGCCCGATCT 180 CCTCCATCTT AGTCTGGATC CACGGCCCCA CCATATTGGC TTGGCTGGCG AACTGTCGGC 240 GAAGGCTGCA TTGGATTGCT 260 (2) INFORMATION FOR SEQ ID NO: 145: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 145: TGACCATCGA TAAGTTTAAT AACTACAGAC TTTTCCCAAG ACTACAAAAG CTTCTTGAAA 60 GTGACTACTT TAGATATTAC AAGGTGAACT TGAAGAAGCC TTGTCCTTTC TGGAATGACA 120 TCAACCAGTG TGGAAGAAGA GACTGTGCCG TCAAACCCTG CCATTCTGAT GAAGTTCCTG 180 ATGGAATTAA GTCTGCCGAG CTACAAGTAT TCTGAGGAAG CCCAACCGCA TTGAAGAATG 240 TGAGCAAGCT GAGCG 255 (2) INFORMATION FOR SEQ ID NO: 146: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 236 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 146: AACTCTGTGA ACCGTGCCTT TCTCTGTGGA GGTGGAGGTG TCGGTTGAAG ACAAGCGAGG 60 TCCTCCAAGG GGCTGTGTCT TATGTTGCCA TCTCCCCTTG TAGCTTGGCT GCCCACCCTC 120 CAGACTGTGC GCCATGGCTC CAAGGCTGTG ACCCGCCACT GGAGTCATGC ACTTCCAGCG 180 GCAGAAGCTG ATGCTATAAC TGAGTATATT CCTCCAAACC TGCCATCAAC CCGAGA 236 (2) INFORMATION FOR SEQ ID NO: 147: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 291 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 147: ACTTCTCCAG AGAATTTAAG ATTGAGAATA GCCCTCGGGA TTTCGCTCTT TACATTATTT 60 TTGGGACAGG AGAGCAGAGA AAGCTAAAGA AGACCGATGT CCCACTGCTG CAGAGGTTAC 120 TACAAGGACC ATCCAAAAGC AATGCTCGGA TCTTCCTCAT GGATAAAGAT GCAGAAGAAA 180 TCAGCAGAGA TGTGGCTCCG TACATTAATT TCACTTTTCT TTCTTGGATC CATCCTTCAA 240 GATTAGATGA AGAAGAGAAA TGGAGATTGA GAGAATATGC AATCATACCG A 291 (2) INFORMATION FOR SEQ ID NO: 148: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 255 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 148: AGGGTTACTT CAGGCTAAGG CAATAGAAAT CCATTTTAAG ATGGTGTGCT AAAGGCTTGA 60 TGGATGTTCA TCGTCTGTCT AAAGGAGAAT GAAGTCATCA ACAGGATGTC AGGGGAAAGT 120 GAGATCATCG CAGAAAGTAT CAACTTAGCA CAAACACACA GGCATAGCTC CTGCAAGAGG 180 TGAATGCTGT CCCCAAATAC CTGAGGAACT ATCCCTTTGG GCAAGAAAAT AGACAAGTCC 240 ATGAAGTCTG GGTGA 255 (2) INFORMATION FOR SEQ ID NO: 149: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 284 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 149: GACCAGGTAC ACTTGAGCAA AGCACCCAGT ATTTAATTCC TTACAGAAAG GAGAGGAAAG 60 GTCTGCAGTT GGACTGATGG TATGCTAACA CCGCAAATGA CTGTCATTTG ATCTCAGAAG 120 TTCAGGATTG ATTGCTATGT TTTAGCTCTA ATTGTGAGAA ACAGTAGTCA TTTTAGTCTT 180 AAATTTTGCC CTCAGGAAAT TCAGGGAGAC TGAGCCTTCC TTCCCCCACC TTCGTAAAGC 240 CGAATTCCAG CACACGGCGG CCGTTACTAG TGGATCCGAG CTCG 284 (2) INFORMATION FOR SEQ ID NO: 150: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 335 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 150: TACAAGGTGG GATGGCAGGA ACTGAAGGCT TCTGTAAATC CAGTTTTGGC TCTCTCTCTG 60 GTCTTTCTTT CTCTTCTGTT CTGTTTGGAA GGGTTTCTGG TCTTTCAGGA GGTATTTTTT 120 TAATTTCATG TTTTCTCTCT GTGGTACCTG CCCCTTGTTT GACGACAGGA GCTGATGGAG 180 GTGGCGGTTT CTTGGGTCTA TTCCCTTCCT TGTCAAAGTC CGATGGAAGT AACTTCACGA 240 AGTTGTCAGG AAACACGCCT CGTCTGCCAT TGAGTTCTCC TTCCCACCAG CCTACGCGAT 300 GCAGTCTTAT TGATGAGAGT CACTATATCT CCTTA 335 (2) INFORMATION FOR SEQ ID NO: 151: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 254 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 151: TCACCCATGA CTTCTATGGA CTTGTCTATT TTCTTGCCCA AAGGGATAGT TCCTCAGGTA 60 TTTGGGGACA GCATTCACCT CTTGCAGGAG CTATGCCTGT GTGTTTGTGC TAAGTTGATA 120 CTTTCTGCGA TGATCTCACT TTCCCCTGAC ATCCTGTTGA TGACTTCATT CTCCTTTAGA 180 CAGACGATGA ACATCCATCA GGCCTTTATG CACACCATCT TAAAATGGAT TTCTATTGCC 240 TTAGCCTGAA GTCC 254 (2) INFORMATION FOR SEQ ID NO: 152: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 241 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 152: CCCATAGAGA TAGGTTTGCT CCAGAACCTG CAGCATTTGC ACATCACAGG GAACAAGGTG 60 GACATTCTGC CAAAACAGTT GTTTAAGTGC GTGAAGTTGA GGACTTTGAA CCTGGGGCAG 120 AACTGTATCG CCTCCCTGCC TGAGAAAATC AGTCAGCTCA CCCAGCTCAC TCAGCTGGAG 180 CTGAAGGGCA ACTGCCTAGA CCGCCTGCCA GCCCAGCTGG CAGTGTCGAT GCTCAAGAAG 240 A 241 (2) INFORMATION FOR SEQ ID NO: 153: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 256 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 153: CAATAATCCA GGTAAAATAG AGTAAAATAG TCTGCTAGCA GCAAGTTCCT ACCATACTTT 60 CAACAACACT CACGAGATAC GGAATGATTA CAGCATTAAG AATATTTCAG AAATGACAGG 120 TAGGTGTGGT GGACAGGTGG CTCACATTCA AGACTCAAGT CTACTTAAAA AAGAAAATCT 180 CACTAGCACT AGATTCTAGC TCCTTTGTTT CCCCCTTTCT TTTGGTTTCA AAGGCGTTTC 240 TACAACCCAT AAGAGG 256 (2) INFORMATION FOR SEQ ID NO: 154: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 154: GCCAAGCTAT TATGACACTA TAGATACTCA ACGTATCGAT CAACGTTGGT ACCGAGCTCG 60 GATCCACTAG TAACGGCCGC CAGTGTGCTG GAATTCGGCT TGGATTGGTC AGAGCAGTGT 120 GCAATATGAT CCAACTAAGT CTCCTCCCTT GGCCCCTCCC CAAAATGTTT GCAGTGTTAT 180 TTTTGTGGGT TTTTTTTTAA CACCCTGACA CCTGTTGTGG ACATTGTCAA CCTTTGTAAG 240 AAAACCCAAA TAAAAATTGA AAAATAAAAT AAAAAGAAAC CCATGAACAT TCGCACCACT 300 TGTGGCTTCT GACTATCTTC CACAGAGGGA AGTTTAAAAC CCAAACTTCC AAAGGTTTGA 360 ACTACCTCAA GACACTTTCG CAGTGGAGTC GTAGACCAAT CCCA 404 (2) INFORMATION FOR SEQ ID NO: 155: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 167 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 155: TAAATAAATT AAAAAACTAT TAAACCTAAA AACGTCCACC AAACCCTAAA ACCATTAAAC 60 AACCAACAAA CCCACTAACA ATTAAACCTA AACCTCCATA AATAGGTGAA GGCTTTAATG 120 CTAACCCAAG ACAACCAACC AAAAATAATG AACTTAAAAC AAAAATA 167 (2) INFORMATION FOR SEQ ID NO: 156: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 212 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 156: GGTAAAGGGG ACCTGGAGAA CGCCTTCCTG AACCTGGTCC AGTGCATCCA GAACAAGCCC 60 CTGTACTTCG CTGACCGGCT GTACGACTCC ATGAAGGGCA AGGGGACTCG AGACAAGGTC 120 TGATTAGAAT CATGGTCTCT CGCAGTGAAG TGGACATGCT GAAAATCAGA TCTGAATTCA 180 AGAGGAATAT GGCAAGTCCT GTACTACTAC AT 212 (2) INFORMATION FOR SEQ ID NO: 157: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 214 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 157: AGAGCAGCAG GCCAGCTGTA CTTGGTTTGG CAAGAAAAAG AAGCAGTACA AAGATAAATA 60 TTTGGCAAAG CACAACGCAG TGTTTGATCA ATTAGATCTT GTCACATATG AAGAAGTAGT 120 CAAACTGCCA GCATTCAAAA GGAAAACATT AGTCTTATTA GGTGCACATG GTGTTGGAAG 180 AAGACACATA AAAAATACCC TCATCACAAA GCAC 214 (2) INFORMATION FOR SEQ ID NO: 158: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 342 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 158: TCGGTCATAG TAGTAAGGGA AATCTCCCAG GTAAGATGAA TACTGCGGTA GGACGAACAA 60 TCCTCCAGGA TGTTTGTTCC ATATTAAACT GTTACGTGAT ATGTGCTTGA ATATTCTGTC 120 CTGAATAATC TCTAGTGTAG TTAATACAAT CTTCTCAACT GAAGAAAAAT AAGCCTCCCA 180 CAAGAACTGT GTCTGCTGTC TAAGTGCTAG GATTTTATCC TGATGAATAG ACCTGATTGT 240 AGAAGGAATC TGTAATAGCA ATCTCTCATC GCCTATGACC GAAAGCCGAA TTCTGCAGAT 300 ATCCATCACA CTGGCCGGCC GCTCGAGCAT CGATCTAGAG GG 342 (2) INFORMATION FOR SEQ ID NO: 159: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 303 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 159: CTGCTTGATG ACAAAGGGTG TAGTCTTCAT CTTTTCCTGG ATTATTTTGG AAGTGACAGG 60 TGGAAATTCC ATCGTCACGT TTATGTGGTC TGTAAAGCCA ACGATCTCAA ATTCTGGCGG 120 CTCAAGAGGA GCGTTTGCAG GCACGATGTA GTCTGAGCAG CGGCACACGG TCAAGTCCCC 180 TCTGTGCACT ATGACGATGG CGACGACGTA GCTCTCCATG CCCTCCAACC ACTTATCTGT 240 CACGTCACAT GATGACTTCG TGGTATCTGA ACAGTTCTTA ACCTTCGTCA GATTTTCGTC 300 TTT 303 (2) INFORMATION FOR SEQ ID NO: 160: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 345 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 160: AAATCGTTGC TTCAGAAAGA CTCAATAACA CTTACTTGTG CCTGGCTGTG CTGACAGTAC 60 ATTCTGTGTC ATTTTCCTTC ATGGGCGGAA CAGTCCACAG AGCTCACCAA CAAGTACTCC 120 AAAACTGAGC AAGAGTTTAA GCTTCGAGAT GCAACCAGAT GAGCTTCTAG AAAAGCCCAT 180 GTCTCCCATG CAGTACGCAC GGTCTGGACT AGGGACAGCA GAGATGAATG GCAAACTCAT 240 AGCTGCAGGT GGTTATAACA GAGAGGAATG TCTTCGAACA GTTGAATGCT ATGATCCACA 300 TACAGATCAC TGGTCCTTCC TTGCTCCCAT GAGAACATCA AGCAG 345 (2) INFORMATION FOR SEQ ID NO: 161: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 315 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 161: CTTTCCGAAG AGCACACCCT CCTCTCAATG AGCTTGTGAG GTCTCTTTCT TCTCTTCCTT 60 CCAACGTGGT GCTAGCTCCA GGCGAGCGAC GTGAGAGTGC CACCTGAGAC AGACACCTTG 120 GTCTCAGTTA GAAGGAAGAT GCAGGTCTAA GAGGAATCCC CGCAGGTCTG TCTGAGCTGT 180 GATCAAGAAT ATTCCGCAAT GTGCCTTTTC TGAGATCGTG TTAGCTCCAA AGCTTTTTCC 240 TATCGCAGAG TGTTCAGTTT GTGTTTGTTT GTTTTTGTTT TGTTTTGTTT TTCCCTTGGC 300 GGATTTCCCG TGTGT 315 (2) INFORMATION FOR SEQ ID NO: 162: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 162: CCTATTGAAC GGTCTTGCAA TGACGAGCAT TCAGATGCTT AAGGAAAGCA TTGCTGCTAC 60 AAATATTTCT ATTTTTAGAA AGGGTTTTTA TGGACCAATG CCCCAGTTGT CAGTCAAAGC 120 CGTTGGTGTT TTCATTGTTT AAAATGTCAC CTATAAAACG GGCATTATTT ATGTTTTTTT 180 TCCCTTTGTT CATATTCTTT TGCATTCCTG ATTATTGTAT GTATCGTGTA AAGGAAGTCT 240 GTA 243 (2) INFORMATION FOR SEQ ID NO: 163: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 243 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 163: CCTATTGAAC GGTCTTGCAA TGACGAGCAT TCAGATGCTT AAGGAAAGCA TTGCTGCTAC 60 AAATATTTCT ATTTTTAGAA AGGGTTTTTA TGGACCAATG CCCCAGTTGT CAGTCAAAGC 120 CGTTGGTGTT TTCATTGTTT AAAATGTCAC CTATAAAACG GGCATTATTT ATGTTTTTTT 180 TCCCTTTGTT CATATTCTTT TGCATTCCTG ATTATTGTAT GTATCGTGTA AAGGAAGTCT 240 GTA 243 (2) INFORMATION FOR SEQ ID NO: 164: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 266 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 164: CCTGGGTCCG TCCTCCAACC CCTCACGCCC AAACCCTCCG ACTTTCACTT CTTGAAGTGA 60 TCGGAAAGGG CAGTTTTGGA AAGGTTCTTC TGGCTAGGCA CAAGGCAGAA GAAGTATTCT 120 ATGCAGTCAA AGTTTTACAG AAGAAGCCAT CCTGAAGAAG AAAGGAAGGA AGCATATTAT 180 GTCAGAGCGG AATGTTCTGT TGAAGAATGT GAAGCACCCT TTCCTGGTGG GCCTTCACTT 240 CTCATTCCAG ACCGCTGACA AGCTCT 266 (2) INFORMATION FOR SEQ ID NO: 165: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 204 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 165: GATGCTGAAC ACAAAAAGAA AGAAGAAAAG GAAGAGGAGG AGCAAGAGAA GCTGAAGGGA 60 GGGAGCCTTG GCGAAAATCA GATCAAAGAT GAGAAGATTA AAAAGGACAA AGAGCCCAAA 120 GAAGAGTCAA GAGCTTCTTG GATAGAAAGA AAGGATTTAC AGAGTGAGGC GCAGAATGGA 180 GATTCATGAC CCACAAACTT AAAC 204 (2) INFORMATION FOR SEQ ID NO: 166: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 200 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 166: AAAGCCAATT GGTAGAGAAA TTGAAGACAC AAATGCTGGA TCAGGAAGAG CTTCTGGCAT 60 CAACCAGAAG GGATCAAGAT AATATGCAAG CTGAACTGAA TCGCCTCCAA GCAGAAAATG 120 ATGCTTCTAA AGAAGAGTAA AGAGTTTTAC AGGCCTTAGA GGACTGCTGT TAATTATGAT 180 CAGAGTTCAG GAGTTAAGAC 200 (2) INFORMATION FOR SEQ ID NO: 167: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 167: CTGCTTGATG TCCTGTGTAG CGAATGTCAC AGCGTACAAC ATTGTTAGTG TAGTCTGATT 60 CAGGCACCAG GTAGCTGGGG TTTACACTGA CCTTTAGAAT GTAGTTTCCA GGTTGTACAT 120 CTGTAATATC AATCCACTGG CAGTCTATGT CTGCCGCATA GGTGTCATAA CATCCAGGAC 180 TCAATCCCTG TGTGTGTGCA GTGCACGCAA AGGCCCTGTG GTACCCATAG TCACAGGACG 240 TGTCCTCCAG ACAGAAGCTT GCTTTGTGGC CTTCAGCCAC TCTCCTCTGT GTGTTGGCAT 300 CAACGAGAAG CCGAATTCTC GAGATATCCA TCACACT 337 (2) INFORMATION FOR SEQ ID NO: 168: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 337 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 168: CTGCTTGATG TCCTGTGTAG CGAATGTCAC AGCGTACAAC ATTGTTAGTG TAGTCTGATT 60 CAGGCACCAG GTAGCTGGGG TTTACACTGA CCTTTAGAAT GTAGTTTCCA GGTTGTACAT 120 CTGTAATATC AATCCACTGG CAGTCTATGT CTGCCGCATA GGTGTCATAA CATCCAGGAC 180 TCAATCCCTG TGTGTGTGCA GTGCACGCAA AGGCCCTGTG GTACCCATAG TCACAGGACG 240 TGTCCTCCAG ACAGAAGCTT GCTTTGTGGC CTTCAGCCAC TCTCCTCTGT GTGTTGGCAT 300 CAACGAGAAG CCGAATTCTC GAGATATCCA TCACACT 337 (2) INFORMATION FOR SEQ ID NO: 169: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 374 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 169: GATCTGACAC TACAGCATGA GCGTTAGATT TCATAAAATT ATTTTTCTTC TAAATGCTGG 60 AAACTCTAAG GGTTTATTCA GAAAAAAAAC TGGCCAATTT TCAAATGGCT TAGAAGCAGG 120 GTTAATTAAG TATTGAATGA GCCACTGTGA TATCCTGATG ACACCCAGTC ACAATGACAG 180 TTTTGAAGCA TACAACCAAA ACAATTGAGA TCTCAAAACT ATTTTACATC ACTTATGGTA 240 ATGTTATGTA AAAATGAAAA TGCTTTCTGT GGAAGTTACA TTCTTTACCA GGTCTTTAAC 300 ATAAATTAAC ACGACGTCGA GTAAGCCTTT GTTCGGAAGA CAAACTAGTT TGTGAGTTCA 360 GTCAGATCCC AGCT 374 (2) INFORMATION FOR SEQ ID NO: 170: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 334 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 170: AGTTGCCAGG ACCACCACCA TAGTTGCCAG GTTCATCATA AACAAATCCA ACATCAATCT 60 TAAATTCCCC CATCAGACAA TCTGCCCTCA AAGAATGGGA ATTATAAACC CGGATACTGA 120 TGATCTCATC CATGAGCTCA GAGGGTGTGA TGTGCACATT GTAGAAAAAT AACTCGTCAA 180 AAAACGGATT GTTCCCTCTC TTGATTCTCG TGCGATGCGT CTGACCACAG ATGTGAACTT 240 TCACCACGGG CCTTATGTTG TTGCCGCATA ACTGACGGCC CTCGATCACT CTGACACGGA 300 TCTGGAAATC TGTGGCTTGT TGGACAGCAT CCTT 334 (2) INFORMATION FOR SEQ ID NO: 171: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 380 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 171: AAGCCGTGTC CCAAAGAATG GATAGAGACG CGATCAGATG CGACAGTGCT GTGGAGAAAG 60 CCCAGGAACC TGCACAATTG CCCTGGTCCA ATGGCTCGTG GATCAGGTTG GGCCACTTCT 120 CTGAAGCTTC AAAGGCAGTG GGTAGCACTT CCCCTTGGCC CAGCACCGTA TAAATCTCAT 180 TCATATTCAT GACAGTGGAG GATGGGCGGA TTGTGCCCAG GCGGTACGGA ATGCCCTCAT 240 CCAGGGTCAT GCCCCAGAAG GCACTGTGGT TCCCAGCCTG CCACCCGTAG TTGCCTCGGT 300 TGATGGCTTT AATCATGTCT GGTCACTAGA CACGGCTTAA GCGAATCTCG AGATATCCAT 360 CACACTGGCG GCGTCGAGAT 380 (2) INFORMATION FOR SEQ ID NO: 172: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 353 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 172: AAGCCGTGTC TGATGATGGA GGTAGTGGTG GGGGAGGAGG GACTGAGGGT CCTGAGGTGG 60 TGGCCCCTGG AACTGATCCC ACATAGTTAC CCACTGCTAG TTCTGACCCC GTGGACAACG 120 TGCCAGAGGC CATGACTGGC AGTATGGCAA TGTCCCCATC CCCTTTCTTC TTAATTTTAA 180 TGGTCCCTTG TTTCTCCAGT TCGTGAATCT TTTTTTCCAG GGTAGACTGT CTTTGAATGG 240 CTTCTTCCTT TTCTTTGACC ATTTTTCTTA ACGTGTGAAC TTGGGTATTT GCATCTTTGT 300 AGATTTCCGG ACAACATCAG TTCCTTATTC CTCTGCATAA GTTGCTTTCA GTT 353 (2) INFORMATION FOR SEQ ID NO: 173: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 350 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 173: CGAGTCAGAC ACATGAAAGC AAAACGCGGG CAGATAAAAC GATCGCCTTA CCTTCTAGCA 60 AAAATCTGAA GCTTGTGTCA GAAACAAAGA CTCAGAAAGG TTTGTTTTCA GATGAAGAAG 120 ACTCTGAGGA TTTGTTTTCT TCTCAAAGTT CAAGTAAGCC AAAAAGTGCA TCACTTTCAT 180 CCAGCCAGCC CCCAACATCA GTCTCCCTTT TTGGTGATGA AGATGAAGAG GACAGTCTTT 240 TTGGGAGTGC AGCAGCTAAG AAGCAGACTT CATCTCTACA ACCTCAGAGT CAAGAGAAAG 300 CAAAGCCTTC CGAGCAGCCC TCAAAGAAGA CATCTGCCTT GTTGTTCAGA 350 (2) INFORMATION FOR SEQ ID NO: 174: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 377 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 174: CGAGTCAGAC TTAATTTAAA AACGAAACAA AACAAAAATA ACATAGTTTA GAAATCAAGG 60 AGAAAGGACA GATAGTCTAA GAAAAAAGAC AACACAAAAG AGGGGCAGGG CGGCCAGCTT 120 GCATCAGGGA TCTTGGCTGG AGACCTGCTT TGAATAGGTT TCTTGCAGGT ATTTCTTAAA 180 TGCTGTGGGG TTTTTCCAGA GTTCCGCAGC GTGTGTGTTC AAAGGGCTAT CGATGTTGGG 240 TTCTCCTAGC AGGCTCTGGA TAGAGAGCAA GATAGTCCTG ACATCATATA GTGCAGACCA 300 CTTATCCTTG AGGATGTCCG GCAGATGTTG CCTGGGTGTC ACGTTGGGGT GGTAGCAGGG 360 TGTGAGGAAC TTCACTG 377 (2) INFORMATION FOR SEQ ID NO: 175: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 326 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (iii) HYPOTHETICAL: NO (iv) ANTI-SENSE: NO (v) FRAGMENT TYPE: <Unknown> (vi) ORIGINAL SOURCE: (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 175: CGAGTCAGAC ACTCCTGGCT CCTGGATTCT TTAGATGCCT CCATCAGACT GGGTACTTTA 60 GATGCCTCCA TCAGACTACT TCGTCATTGT ATTTCTCAGT TCGCTCAGGG CAAGCGGCAG 120 TCTCTGGGCT GCTGTGGCAG GTGCCACCAC TGCATTTAAA AGTTAAAATT TCTTCAAATA 180 TTCCCATCAA GGCCTTGTAG CCTCTGAGAT TGGTTTACTA TTTGCCCAGT TATTTAAAGC 240 TCTCTGCATT CCTTCCTGAT TTAATATTGC TATGGCCAGG ACAATGTGTA GAAGTAAAAA 300 GGATATCATA TTTACAGGTG TAACGC 326

Claims

1. A method for identifying a sequence expressed in a metastasis comprising the steps of:

a) transfecting an oncogenic sequence into a mammalian cell to form a population of transfected cells;

b) administering tranfected cells to a primary site of a host mammal to form a primary tumor;

c) maintaining said mammal for a period of time sufficient to develop a metastasis at a secondary site;

d) amplifying expressed RNA sequences of the transfected cells and expressed RNA sequences of the metastasis by differential-display PCR; and

e) comparing the amplified expressed RNA sequences of the transfected cells with the amplified expressed RNA sequences of the metastasis and identifying the sequence expressed at a higher level in the metastasis as compared to the expressed RNA sequences of the transfected cells.

2. The method of claim 1 wherein the mammalian cell is transfected by calcium phosphate transfection, viral transduction, lipofection, dextran sulfate transfection or electroporation.

3. The method of claim 1 wherein the oncogenic sequence is a sequence of the gene that erodes the oncoproteins p21, p34, p53, myc, ras or src.

4. The method of claim 1 wherein the oncogenic sequence is a sequence that enhances metastatic potential.

5. The method of claim 4 wherein the oncogenic sequence is a sequence of the gene that encodes cyclin D1, caveolin or TGF-&bgr;1.

6. The method of claim 1 wherein the mammalian cell is treated with an agent that alters gene expression prior to the administration of said cell to said host mammal.

7. The method of claim 6 wherein the agent is benzanthracene (BA), dimethyl benzanthracene (DMBA) or 5-azacytidine.

8. The method of claim 1 wherein the mammalian cell is a primary cell or an established cell line.

9. The method of claim 1 wherein the mammalian cell is isolate from urogenital sinus tissue.

10. The method of claim 1 wherein the mammalian cell is a fetal cell.

11. The method of claim 1 wherein the mammalian cell contains a gene selected from the group consisting of TGF-&bgr;1, cyclin D1, p21, p34, p53, ras, and myc.

12. The method of claim 1 wherein the mammalian cell is isolated from the same species as the host mammal.

13. The method of claim 1 wherein the mammalian cell and the host mammal are histocompatible.

14. The method of claim 1 wherein the mammalian cell and the host mammal are syngeneic.

15. The method of claim 1 wherein the transfected cell is isolated and maintained in vivo or in vitro for a period of time prior to introduction of said cell to the host mammal.

16. The method of claim 1 wherein the expressed sequences of the transfected cells are obtained from a cell line of immortalized transfected cells.

17. The method of claim 1 wherein the transfected cells are administered to the primary site by subcutaneous implantation.

18. The method of claim 1 wherein the host mammal is a mouse, a rabbit or a primate.

19. The method of claim 1 wherein the host mammal is a syngeneic, xenogeneic, immunocompromised or transgenic host mammal.

20. The method of claim 1 further comprising suppressing expression of TGF-&agr; in the host mammal prior to the introduction of transfected cells into said host mammal.

21. The method of claim 1 wherein the primary site is the renal capsule, the prostate or the testis.

22. The method of claim 1 wherein the secondary site is selected from the group of sites consisting of lung, kidney, liver, lymph nodes, brain, bone, testis, spleen, ovaries and mammary.

23. The method of claim 1 wherein differential display PCR is performed with an anchor primer and a variable primer.

24. The method of claim 22 wherein the anchor primer comprises a polythymidine sequence and a dinucleotide sequence connected to a 3′-terminus.

25. The method of claim 24 wherein the polythymidine sequence comprises between about 5 to about 30 thymidines.

26. The method of claim 24 wherein the dinucleotide sequence is selected from the group of sequences consisting of AA, AG, AC, AT, GA, GG, GC, GT, CA, CG, CC and CT.

27. The method of claim 23 wherein the anchor primer or the variable primer comprise a detectable moiety selected from the group consisting of radioactive moieties, phosphorescent moieties, magnetic moieties, luminescent moieties and conjugatable moieties.

28. The method of claim 23 wherein the anchor primer and the variable primer have a common sequence.

29. The method of claim 7 wherein the agent is a retinoid.

30. A method for identifying a sequence expressed in metastasis comprising the steps of:

a) pretreating a mammalian cell with an agent that enhances metastatic potential to form a population of cells predisposed to metastasis;

b) introducing the pretreated cells to a primary site of a host mammal;

c) maintaining said mammal for a period of time sufficient to develop a metastasis at a secondary site;

d) amplifying expressed RNA sequences of pretreated cells and expressed RNA sequences of the metastasis by differential-display PCR; and

e) identifyg the sequence expressed at a higher level in the metastasis as compared to expressed RNA sequences of the pretreated cells.

31. The method of claim 30 further comprising the step of treating cells of the primary or secondary sites with a genotoxic agent prior to amplification.

32. The method of claim 31 wherein the genotoxic agent is benzanthracene (BA), dimethyl benzanthracene (DMBA) or 5-azacytidine.

33. The method of claim 30 further comprising the step of comparing the expressed sequences amplified from the metastasis with expressed sequences amplified from mammalian cells before pretreatment to identify the sequence selectively expressed in the metastasis.

34. The method of claim 30 wherein the chemical compound is a benzanthracene, dimethyl benzanthracene, or 5-azacytidine.

35. The method of claim 30 wherein the mammalian cell is transfected, prior to the administration of said cell to the host mammal, with an oncogenic sequence before or after treatment of said cell with the agent that enhances metastatic potential.

36. The method of claim 30 wherein the mammalian cell is a cell line.

37. The method of claim 30 wherein the mammalian cell is isolated from lymphatic tissue, hematopoietic cells, reproductive tissues or urogenital sinus tissue.

38. The method of claim 30 wherein the mammalian cell is a fetal cell.

39. The method of claim 30 wherein the mammalian cell is isolated from a transgenic animal.

40. The method of claim 30 wherein the primary site is the renal capsule, the prostate or the testis.

41. The method of claim 30 wherein the secondary site is selected from the group of sites consisting of lung, kidney, liver, lymph nodes, brain, bone, testis, spleen, ovaries and mammary.

42. The method of claim 30 wherein differential display PCR is performed using an anchor primer and a variable primer.

43. A method of screening a biological tissue for the presence of a metastasis comprising contacting the tissue with a nucleic acid probe, wherein the probe detects the presence of a nucleic acid molecule comprising SEQ ID NO: 89 or its complement, and wherein an increased level of a nucleic acid molecule comprising SEQ ID NO: 89 or its complement in the biological tissue relative to the level of a nucleic acid molecule comprising SEQ ID NO: 89 or its complement in a primary tumor is indicative of a metastasis.

44. The method of claim 1, wherein the tissue is lung, kidney, liver, lymph node, brain, testis, bone, spleen, ovary, or mammary tissue.

45. The method of claim 1, wherein the tissue is renal capsule, testis, prostate, or ovary tissue.

46. The method of claim 1, wherein the method comprises in situ hybridization of the probe with the tissue.

47. The method of claim 1, wherein nucleic acids are extracted from the tissue prior to contact with the probe.

48. The method of claim 5, wherein the nucleic acids are amplified prior to contact with the probe.

49. The method of claim 6, wherein the method comprises different display polymerase chain reaction.

50. The method of claim 1, wherein the primary tumor in a prostate tumor.